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ABSTRACT OF THESIS

MINIMUM INHIBITORY CONCENTRATIONS OF
TWO COMMON FOOD PHENOLIC COMPOUNDS AND THEIR
EFFECT ON THE MICROBIAL ECOLOGY OF SWINE FECES IN VITRO
Feeding sub-therapeutic levels of antibiotics to livestock has been associated with
development and spread of antibiotic resistant bacteria. The present experiment was conducted
to investigate the effect of antibiotic alternatives (caffeic acid, chlorogenic acid, and carbadox)
on the microbial ecology of swine feces in vitro.
Minimum inhibitory concentrations of caffeic and chlorogenic acids were determined for
several pathogens using macrobroth and agar dilution techniques. Gram-negative bacteria were
not inhibited. Caffeic acid inhibited four Staphylococcus aureus strains at 200 ppm or less, and
two Clostridium perfringens strains at 300 ppm. Chlorogenic acid inhibited all S. aureus strains
at 500 ppm, and one C. perfringens strain at 400 ppm.
Effects of antibiotic alternatives on fecal microbial ecology were determined using an in
vitro incubation. Caffeic acid lowered total anaerobes, Bifidobacteria, Escherichia coli, and
percent E. coli (p<0.01). Chlorogenic acid lowered total anaerobes, Bifidobacteria, and
lactobacilli (p<0.01), and increased acetate concentration (p<0.0001). Carbadox lowered total
anaerobes, Bifidobacteria, E. coli, and coliforms (p<0.01), and lowered acetate, propionate,
butyrate, valerate, and total volatile fatty acid concentrations (p<0.01). It can be concluded that
addition of caffeic acid, chlorogenic acid, or carbadox effected bacterial and chemical
components of the microbial ecology of swine feces.
KEYWORDS: Food phenolics, caffeic acid, chlorogenic acid, in vitro, microbial ecology.
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CHAPTER 1
Introduction
Shortly after the introduction of antibiotics to the public, bacteria resistant to antibiotics
emerged. Antibiotic resistance is a self-preservation technique inherent to the microorganism or
acquired through microbial genetics. Complications associated with resistance include crossresistance, multiple-drug resistance, increased virulence, and difficulty in treating disease.
The development of resistance occurs in two main reservoirs, humans and animals.
Humans often misuse antibiotic therapy. Antibiotics are also frequently used in the livestock
industry. They have been used as feed supplements for over 50 years at sub-therapeutic levels to
promote growth. Scientists have linked this practice to the development and spread of resistance
in humans.
Resistant bacteria can be transported from human to human, animal to animal, and animal
to human through direct or indirect contact, including the consumption of food. Another
problem emerges if the resistant bacteria are pathogens that cause foodborne illness. Each year,
an estimated 5.2 million people suffer from foodborne bacterial gastroenteritis (Mead et al.,
1999). Salmonella, Campylobacter, Escherichia coli, and Clostridium perfringens are leading
causes of bacterial foodborne illnesses. Antibiotic resistance in these pathogens may induce
increased survivability and toxin production, resulting in prolonged illness or heightened severity
of disease.
There are several ways to address the growing problem of antibiotic resistance.
Discovery and creation of new antibiotics by scientists occur, but may not be practical. The role
of antibiotic use in humans and animals can be altered. The prudent use of antibiotics and
improved hygiene can decrease the development and spread of resistance. In addition, when
antibiotics are removed from livestock diets, level of resistance decreases. For these reasons,
The European Union (EU) has already banned several growth promoting antibiotics used in
animal feeds.
Antibiotics are confirmed to improve growth performance in livestock compared to nonantibiotic supplementation, translating into a bigger profit for the farmer. However, growing
public concern about antibiotic resistance is forcing farmers to seek out alternatives.
Alternatives to antibiotics can be implemented without a lengthy approval process through the
Food and Drug Administration (FDA). Well-studied alternatives include probiotics and
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prebiotics, which have demonstrated improved growth characteristics and disease prevention.
Yet, few studies exist on the effect of functional foods or herbs included in livestock diets.
To be included in a diet, a feed or feed supplement must be proven safe as well as
improving growth performance or preventing disease. This can be accomplished through
scientific studies. To develop a true understanding how diet effects an animal and the food it
produces, studies must be done on many levels. One level includes specific chemicals found in
food and how they may effect the animal in a variety of ways.
The chemical composition of a food plays a major role in its functionality. Phenolic
compounds are a major group of biologically active chemicals found in plants (phytochemicals),
and have been found to have antimicrobial, antioxidant, and anticarcinogenic activities. Some of
the most common phenolic compounds found in foods of plant origin are the hydroxycinnamic
acids (HCA), including caffeic acid (CFA) and chlorogenic acid (CGA).
Phytochemicals may have an effect of the microbial ecology of the gastrointestinal tract.
The microbial ecology of animals plays a major role in the overall health of the animal. Healthy
animals have decreased illnesses and improved growth characteristics. Understanding how diet
affects microbial ecology is important to livestock producers as well as consumers. Therefore,
the objectives of this study were:
1) To determine the minimum inhibitory concentrations of caffeic acid and chlorogenic
acid against selected Gram-negative and Gram-positive pathogens.
2) To determine how caffeic acid and chlorogenic acid effect the fecal microbial ecology
of swine in vitro.
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CHAPTER 2
Literature Review
Antibiotic Resistance
Antibiotics were discovered as early as 1888 in Germany but were toxic to mammals and
unstable. Although Alexander Fleming discovered penicillin in Britain in 1929, it was not
introduced to the public until 1942. Shortly after, in 1945 Fleming warned of selecting for
mutant bacteria resistant to penicillin (Levy, 1992). Since then, antibiotics have been widely
used for the prevention and treatment of disease in humans. Pharmaceutical companies have
provided large quantities for human and animal use. However, bacterial resistance to antibiotics
threatens the ability of doctors to keep the human population healthy.
Definitions. Antibiotics are not novel biological agents, but very common microbial
products. Using a strict definition, an antibiotic is a chemical produced by a microorganism that
has the ability to inhibit the growth of bacteria, or kill bacteria and other microorganisms
(Scholar and Pratt, 2000). This is a self-preservation technique used by many microbes. This
definition has broadened to include synthetic and semi-synthetic antibiotics created by scientists.
Yet, the definition of an antibiotic fails to consider other materials such as plants and the
compounds derived from them. These materials are considered chemotherapeutic agents
(Jurgens, 1997), and can also be called antimicrobials. In the end, the results can be the same,
bacteriostatic or bactericidal effects. Bacteriostatic compounds inhibit bacterial replication and
growth, while bactericidal compounds cause bacterial cell death and lysis (Scholar and Pratt,
2000). Bacteriostatic drugs do not kill invading pathogens, but they allow the host’s immune
system to catch up in the infection battle. Growth of invading pathogens is put on hold giving
the host’s immune system more time to respond and rid the body of infection.
Mechanisms of resistance. Antibiotics work by targeting specific areas of the bacterial
cell: preventing proper cell wall synthesis, interfering with nucleic acid or protein production,
inhibiting chromosome replication and function, interference of folate metabolism, and
compromising membrane permeability (Scholar and Pratt, 2000). Ideally, an antibiotic will only
affect the infecting organism and will not harm host cells (selective toxicity).
Antibiotic resistance occurs when a bacterium is not sensitive to an antibiotic and
continues to grow. Some bacteria have intrinsic resistance. The microorganism may lack a
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specific drug receptor, or have protective characteristics such as the Gram-negative outer
membrane which prevents the antibiotic from entering the cell (Scholar and Pratt, 2000). Grampositive bacteria do not have this protective outer membrane (Hancock, 1997).
Resistance may also be acquired. The bacterium identifies an antibiotic as an
environmental toxin. The microbe may initially be sensitive to an antibiotic, but undergoes a
change in order to become less sensitive or completely insensitive. The change occurs through
an assortment of biochemical mechanisms including decreased uptake of the drug, increased
efflux of the drug, enzymatic inactivation of the drug, and altered target receptor (Scholar and
Pratt, 2000).
Acquired resistance may occur by a mutation in the bacterial genome or through
obtaining genetic information for resistance from another bacterium. Hundreds of different
genes encode for biochemical mechanisms of resistance. Resistance may occur to only one
antibiotic; still, one antibiotic can also trigger multi-drug resistance (George and Levy, 1983;
Levy et al., 1976).
Development of resistance. The main reservoirs of antibiotic resistant bacteria include
humans and animals. Causes for development of resistance include over-prescription by doctors,
prophylactic treatment (prevention of disease) of hospitalized patients, misuse of antibiotics by
patients at home, and use of antibiotics in agriculture. Today, doctors are better educated on
consequences of over-prescription. Doctors are prescribing antibiotics less and educating their
patients, making them more aware that following directions for the prescription is important
(Williams and Heymann, 1998). However, the use of antibiotics in the livestock industry is
commonplace around the globe and consequently contributes to the development and spread of
antibiotic resistance.
Therapeutic and subtherapeutic antibiotic use in animals accounts for half of the world’s
antibiotic output (Perreten et al., 1997). Feeding antibiotics to animals was commercially
introduced in 1959. In animal production, high doses of antibiotics are applied to feed, drinking
water, or by injection for short periods of time to cure disease. The more common use is in low
doses (below therapeutic levels) administered in feed for a long period of time to prevent disease
and improve performance. The result is a decrease in the amount of feed required to produce a
unit of gain in body weight, and lower morbidity and mortality rates. This translates into greater
profit for the farmer (Strauch, 1987c).
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Exposure to antibiotics in high or low doses creates resistance in bacteria. Some bacteria
return to previous sensitivity, while others remain unchanged after hundreds of generations in
antibiotic-free media (Strauch, 1987c). However, bacterial ecology of mammals is very
complex. Skin/hide, respiratory, and gastrointestinal microbes include bacteria, fungi, protozoa,
and viruses. These microbes are biologically linked, and when one group is affected, the others
are as well. Resistance creates a selective pressure on the bacterial populations. The organisms
with resistance will continue to reproduce, and the ones lacking resistance will perish. In the
presence of the antibiotic, this selective pressure causes a shift towards resistant microflora of the
host.
Intensively managed animals, such as swine, receive more antibiotics than other animals,
such as cattle or sheep on pasture. They carry large numbers of antibiotic resistant Escherichia
coli in their intestinal flora (up to 90%), and they become established components of the gut and
persist even in the absence of antibiotics (Linton et al., 1976).
Spread of resistance. The spread of resistance occurs through transfer of genetic
material from a resistant bacterium to a sensitive one. Genetic material may include plasmids,
transposons, integrons, phages, and other elements capable of mobility.
Plasmids are circular, extrachromasomal (not on the chromosome), double-stranded
DNA. They have the ability to replicate independently of the host bacterial cell. Most resistance
in bacteria is plasmid-mediated, and one plasmid usually encodes for resistance to more than one
antibiotic (Salyers and Shoemaker, 1994). Specifically, R-plasmids encode for antibiotic
resistance. They can be transferred to other bacteria through the process of conjugation.
Conjugation is a “mating” process used by bacteria to transfer genetic information from the
donor to a recipient (Strauch, 1987c).
Transposable elements (transposons) are mobile extrachromasomal linear DNA that can
recombine into the genome at random or at particular “hotspots.” Transposons can occur on the
chromosome or on plasmids. They often encode for enzymes involved in antibiotic resistance.
The ability of a transposon to jump from one site to another (plasmid to plasmid, plasmid to
chromosome, chromosome to plasmid) does not require help from the bacterial cell. The
transposon’s genes encode for enzymes needed for its own mobilization. Once the transposon is
on a conjugative plasmid, it can be transferred to another bacterium. There can be multiple
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transposons on a single plasmid (Lewin, 2002). Other transposons have the ability to conjugate
themselves (Salyers and Shoemaker, 1994).
More recently discovered, integrons are linear segments of extrachromasomal DNA.
Unlike transposons, they integrate at a specific site with an 8 base pair consensus sequence.
They require plasmid-encoded enzymes to integrate into DNA and rely on the plasmid’s
promoter (a region of DNA involved in the initiation of transcription) to activate resistance
genes. Several integron resistance genes can be inserted end to end and be controlled by one
promoter. (Salyers and Whitte, 1994).
Another important mechanism of transfer is the bacteriophage. A bacteriophage is a
virus that infects bacteria (also known as a phage). The phage binds to the outer bacterial
membrane and injects its DNA (or RNA) into the cell. Once inside the cell, the genetic material
can incorporate itself into the chromosome. Inserted phage DNA could contain a transposon
encoding for antibiotic resistance as well as other virulence factors (Lewin, 2000; Salyers and
Whitte, 1994).
There are numerous examples of bacteria able to transfer resistance, even in the absence
of antibiotics. Virginiamycin resistant Enterococcus faecium isolated from pigs and broilers was
able to transfer its resistance to a sensitive E. faecium (Hammerum, et al., 1998). The transfer, or
spread, is not limited to specific bacterial strains or even species. Resistance can be transferred
from one genera to another. Resistant Salmonella was able to transfer its resistance to an E. coli
(Tessi et al., 1997). Gram-negative E. coli was able to transfer resistance into the Gram-positive
Clostridium perfringens (Kaufmann et al., 1996). The multi-drug resistant Lactococcus lactis
spp. lactis K214 isolated from a raw milk soft cheese was able to transfer its resistance to
Enterococcus faecalis (Perreten et al., 1997). The ability of a non-pathogen to transfer its
resistance to pathogens that can cause disease is an obvious concern to humans.

There is even

an example of trans-kingdom transfer of antibiotic resistance from an E. coli to the yeast
Saccharomyces cerevisiae (Heinemann and Sprague, 1989).
Resistance can spread directly from animal to animal or animal to human. Bacteria can
be excreted from an animal in a number of ways: mucosal secretions, feces, urine, milk, blood,
and sperm (Strauch, 1987b). Bacteria and/or their spores may also become airborne (Strauch,
1987a). A farmer that works directly with livestock faces several microbial hazards. First, if the
bacterium is a pathogen, he risks illness. Second, if the bacterium is resistant to antibiotics, the

6

resistance can be transferred to his own microflora. Farmers may also be in direct contact with
animal feed that contains antibiotics. People working with farm animals have a higher
percentage of antibiotic resistant E. coli in their intestinal microflora compared to the nonfarming community (Levy et al., 1976).
Finally, resistance can spread from animal to food to human. Food is the direct link
between microflora of an animal and the non-farming community. As previously discussed,
antibiotic resistant bacteria have been isolated from animals as well as their food products. For
meat products, it is not possible to slaughter an animal without contaminating the carcass with
intestinal and skin/hide microflora (Jackson et al., 1997). Linton et al. (1977) were able to show
resistant bacteria from chickens were carried along the food chain and colonized in man.
Significance of antibiotic resistant bacteria. Virulence is the degree to which a
pathogen can cause disease. Antibiotic resistance has been associated with virulence factors. In
one particular strain of E. coli isolated from piglets with diarrhea, genes controlling the
production of enterotoxins were located on the same plasmid that encoded for tetracycline,
streptomycin, and sulfonamide resistance (Gyles et al., 1977). The H2 plasmid carries resistance
to chloramphenicol, kanamycin, streptomycin, and tetracycline. This plasmid was linked to
enhanced survivability in calf intestines when tetracycline was introduced in the diet (Timoney
and Linton, 1982).
Antibiotic resistance can not only increase the severity of disease it also makes treatment
of diseases more difficult. Staphylococcus aureus can infect any part of the human body and is
the main cause of bovine mastitis (Tueber, 1999). The most common cause of urinary tract
infection is E. coli (Strauch, 1987c). Resistant strains are more difficult to eliminate and
treatment becomes more costly.
Although some antibiotics fed to animals are not the same ones specifically prescribed to
humans, there are other complications such as cross-resistance. For example, vancomycin is
used for human therapy, while avoparcin is used in animal husbandry. Both antibiotics have the
same mode of action by inhibiting cell wall synthesis, and resistance to one can render resistance
to the other. The resistant bacteria can be transferred to humans by physical contact with the
animal or through food (Witte, 1998).
Different components of the food chain are intricately intertwined (Figure 1). An
example of this occurred in the former East Germany. The antibiotic streptothricin was used as a
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Figure 1. Network of Resistance. Adapted from Witte, W. 1998. Medical Consequences of
Antibiotic Use in Agriculture. Science. 279: 996-997. Main reservoirs of antibiotic resistant
bacteria include circled items. Antibiotics act as selective pressures on the main reservoirs. All
arrows indicate routes of transmission.
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growth promoter in pigs from 1982 to 1990. In 1984, resistance to the antibiotic was found in E.
coli isolated from the gut flora of farm employees and their family members. By 1985, resistant
E. coli were found in the urban population, milk and meat products, sick animals, and patients
with urinary tract infections. Before the end of application in the early 1990’s, resistance was
found in bacteria causing the illnesses salmonellosis and shigellosis (Tschape, 1994).
Interactions between human, animal, plant and environmental bacterial ecologies lead to an
increase in the occurrence of antibiotic resistant pathogens. The threat of infection from a
resistant, untreatable foodborne pathogen is increasing and becoming a significant risk in daily
life (Mazel and Davies, 1999).
Foodborne Pathogens
Each year, an estimated 14 million people suffer from foodborne bacterial gastroenteritis
(Mead et al., 1999). Food contains multiple nutrients that may support the growth of many
pathogenic (disease-causing) bacteria. Gastroenteritis is a general term and refers to acute
infectious diarrhea. The diarrhea usually lasts less that 2 weeks and may be accompanied by
nausea, vomiting, fever, and abdominal pain (Schlossberg, 2001). From 1991 to 1993, bacterial
foodborne illnesses cost Americans $2.9-$6.7 billion dollars annually, and the number of
antibiotic resistant pathogens rises each year (CDC, 1998). A major challenge to human health
is antibiotic resistance in foodborne pathogens. The resistance can develop by exposure to an
antibiotic or occur through transfer of resistance genes from another bacterium as discussed in
the previous section. Some of the major microorganisms causing foodborne illnesses are
discussed here.
Salmonella. Salmonella species are Gram-negative rods that occur widely in nature.
They are commonly found in the intestinal tracts of humans and animals. The organisms are
excreted in feces and may be transported to numerous places, including water and food (Jay,
1996).
The genus Salmonella is divided into only 2 species, S. enterica and S. bongori. There
are 6 subspecies within S. enterica (Table 1). Nearly all disease causing serotypes belong to this
subspecies (Fierer and Guiney, 2001). Currently there are 1,478 serovars belonging to S.
enterica subsp. enterica (Popoff et al., 2001). In this text, serovars are treated as species. For
example, S. enterica subsp. enterica serovar Typhimurium will be referred to as S. typhimurium.
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Table 1. Current number of Salmonella serovars.a
Species
S. enterica
subsp. enterica
subsp. salamae
subsp. arizonae
subsp. diarizonae
subsp. houtenae
subsp. indica
S. bongori
Total
a
From Popoff et. al., 2001.

Number
1478
498
94
327
71
12
21
2501
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Salmonella species cause salmonellosis (gastroenteritis) and are responsible for an
estimated 1.5 million bacterial foodborne cases each year. They cause an estimated 25% of
hospitalizations and 31% of deaths caused by all foodborne illnesses, including bacterial,
parasitic, and viral cases (Mead et al, 1999). Salmonella typhimurium and S. enteritidis are the
most common isolated foodborne serovars (CDC, 2002). Foods associated with Salmonella
involve raw meats, eggs, dairy products, raw fruits and vegetables, and water (CDC, 2001).
Infective dose may be very low depending on age and health of host as well as differences
among bacterial strains. In New York city, an outbreak of salmonellosis was due to non-dairy
ice cream, and 150 viable salmonellae per gram of food were found (Armstrong et al., 1970).
Symptoms usually appear in 12-72 hours and include nausea, vomiting, abdominal pain, chills,
headache, and diarrhea and lasts 4-7 days (Schlossberg, 2001).
Most cases do not require treatment of antibiotics unless the infection does not clear up or
the infection spreads. Complications following salmonellosis include septicemia (blood
infection), reactive arthritis, and Reiter’s syndrome (Petersen et al., 1996). Reiter’s syndrome
consists of urethritis (or cervicitis), conjunctivitis, and arthritis (Dworkin et al, 2001).
Resistance is important because of increased virulence and inability to treat the disease in
humans and animals. Multi-drug resistance was found in 96% of S. typhimurium isolates from
swine in North Carolina (Gerbreyes et al., 2000). A particularly virulent stain, S. typhimurium
DT104, carries phage DNA with a typical multidrug-resistance pattern to ampicillin,
chloramphenicol, streptomycin, sulfonamides, and tetracyclines. This phage type has also shown
resistance to trimethoprim, spectinomycin, and ciprofloxacin (Teuber, 1999). Incidence of this
multidrug-resistant organism is on the rise. In 1979-1980, occurrence of S. typhimurium isolates
with a five-drug resistance pattern was 0.6%. In 1996, 34% of isolates displayed this pattern
(Glynn et al., 1998). Fluoroquinolones are often prescribed to ill patients. However, an outbreak
of DT104 in Denmark in 1998 proved difficult. The bacteria isolated had reduced sensitivity to
fluoroquinolones. Out of 25 confirmed cases, 11 were hospitalized and 2 patients died (Mølbak
et al., 1999).
Escherichia coli. Escherichia coli is a Gram-negative rod and is present as intestinal
microflora of humans and animals. Fecal contamination of foods and water are responsible for
E. coli gastroenteritis (Jay, 1996).
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Five virulence types are recognized as a possible cause of gastroenteritis:
enterohemorrhagic E. coli (EHEC), enteroinvasive E. coli (EIEC), enteropathogenic E. coli
(EPEC), enterotoxigenic E. coli (ETEC), and more recently enteroaggregative E. coli (EAggEC)
(Levine, 1987). Foods associated with E. coli gastroenteritis include beef, unpasteurized milk
and juice, raw fruits and vegetables, salad dressings, salami, and contaminated water (CDC,
2001).
EPEC and EIEC generally do not produce toxins. EPEC strains cause diarrhea in
children under 1 year of age (Donnenberg and Kaper, 1992), and EIEC strains can cause
voluminous bloody or non-bloody diarrhea (Levine, 1987). ETEC strains produce enterotoxins
resulting in profuse watery diarrhea with a very sudden onset, and is a well known cause of
traveler’s diarrhea (Levine, 1987). Onset of symptoms for EPEC, EIEC, and ETEC is between
12 and 72 hours, and infective doses range between 105-107 viable cells (Eley, 1996). EAggEC
strains produce enterotoxin (Savarino et al., 1991) and cause persistent diarrhea that lasts for
over 2 weeks (Bhan et al., 1989).
EHEC strains produce Shiga-like toxins (SLT) and can cause hemorrhagic colitis (bloody
diarrhea), severe abdominal cramps, nausea, and vomiting. Symptoms appear after an incubation
period of 1-8 days and last for 5-10 days (CDC, 2001). The most well known strain, EHEC
serotype O157:H7, was not recognized as a cause of human illness until 1982 (Bean and Griffin,
1990). Infective dose for EHEC O157:H7 is thought to be low, as few as 10 organisms causing
illness (Keene et al., 1994; Willshaw et al., 1994).
Hemolytic uremic syndrome (HUS) is an illness that can develop from infection of SLT
producing bacteria and may be associated with antibiotic therapy. The syndrome consists of
hemolytic anemia, thrombocytopenia, and acute renal failure. Wong et al. (2000) conducted a
study of children infected with E. coli O157:H7 gastroenteritis. HUS developed in 14%, half of
which had previously received antibiotics. They concluded that antibiotic treatment of children
with this type of infection increases the risk of developing HUS.
An estimated 270,000 illnesses per year are attributed to all E. coli infections, 74,000
from O157:H7, 37,000 from other Shiga-toxin producing E. coli (STEC) and 159,000 from nonSTEC. However, STEC strains account for an estimated 5% of hospitalizations and 4% of
deaths related to all foodborne illnesses, including bacterial, viral, and parasitic infections (Mead
et al., 1999).
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Antimicrobial therapy is generally not effective and could increase virulence. Antibiotic
resistant E. coli have shown an increased ability to colonize the intestines (Timoney and Linton,
1982). Antibiotic treatment of EHEC infections is very controversial. SLT is encoded for by
bacteriophage DNA (Schmidt, 2001). Antibiotics induce the phage lytic cycle via the SOS
pathway (Fuchs et al., 1999). The SOS response is induced by DNA damage or inhibition of
DNA replication. The lytic cycle involves mass-production of more phages, as well as SLTs.
When cells lyse, phages and toxins are released, resulting in more damage to the patient (Neely
and Friedman, 1998). Olaquindox and carbadox are used as growth promoters in the livestock
industry and have been shown to increase toxin production in the same manner. This may
influence transfer of virulence genes between microbes of the animal, increasing development
and spread of new SLT producing bacteria (Köher et al., 2000).
There is evidence of increasing numbers of antibiotic resistant E. coli O157:H7 strains.
Isolates collected between 1984-1987 were all sensitive to antibiotics. From 1989-1991, 7.4% of
strains isolated were resistant to streptomycin, sulfisoxazole, and tetracycline (Kim et al., 1994).
Not only is virulence increased, but the prevalence of this pathogen in food animals is increased.
Campylobacter jejuni. Campylobacter jejuni is a microaerophilic Gram-negative curved
rod and is a common inhabitant of the intestinal tract of animals. This particular bacterium is
quite fastidious and requires reduced oxygen (approximately 5%) and about 10% carbon dioxide
for good growth in the laboratory. They are difficult to grow and stress such as exposure to air,
drying, low pH, heating, and freezing hinder recovery (BAM, 1998). They do not grow at 25°C,
and the optimum for growth is 42°C. Despite these hurdles, they can survive at 4°C for 2-4
weeks (Blaser et al., 1980).
Campylobacter infections cause campylobacteriosis (campylobacter enteritis or
gastroenteritis). The majority of cases (over 90%) are attributed to C. jejuni. Other
Campylobacter recognized as a cause of gastroenteritis include C. coli, C. fetus, and C.
upsaliensis (McClellan et al., 2002). Foods associated with Campylobacter include poultry,
unpasteurized milk, and contaminated water (CDC, 2001). However, C. jejuni has been isolated
from many sources, including hamburger, cattle feces, sheep carcasses, and swine carcasses
(Blaser, 1982). Symptoms of campylobacteriosis include watery diarrhea that may contain
blood, fever, abdominal pain, nausea, headache, and muscle pain. Incubation period is 1-7 days
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and the symptoms last about a week (Schlossberg, 2001). Infective dose is small, 800 cells being
able to cause disease depending on bacterial strain (Black et al., 1988).
Surveillance has been limited due to a couple of factors. First, the organism requires
special laboratory equipment to provide the proper environment for recovery and growth. In
addition, this bacterium was not reported as a cause of foodborne illness until 1980 (Bean and
Griffin, 1990). It is now thought that C. jejuni is the leading cause of bacterial diarrhea in the
United States. Each year, estimates exceed those for salmonellosis at 2.5 million cases per year.
They cause an estimated 17% of hospitalizations and 6% of deaths caused by all foodborne
illnesses, including bacterial, parasitic, and viral cases (Mead et al, 1999). Complications of
infection include septicemia, HUS, reactive arthritis, and Guillain-Barré syndrome, which can
lead to temporary paralysis (Walder et al., 1982; Berden et al., 1979; Rhodes and Tattersfield,
1982).
Because campylobacteriosis is so prevalent, antibiotic resistance becomes a major
concern. Sánchez et al. (1994) found a trend of increased quinolone resistance in C. jejuni
isolates. On the average, 0% of strains tested were resistant in 1988 and 54% in 1992. Reina et
al. (1994) had similar results, and reported an increase in tetracycline resistance. Tetracycline
resistance is plasmid-mediated (Taylor et al., 1983) and reports of resistance may depend on
specific strain and/or geographical area. The National Antimicrobial Resistance Monitoring
System began surveillance on resistant Campylobacter in 1997. They discovered that
fluoroquinolone resistance was on the rise, and patients infected with resistant bacteria had a
longer duration of diarrhea compared to non-resistant infections (McClellan, 2002). Engberg et
al. (2001) discuss emerging quinolone resistance in C. jejuni and link it to antibiotic use in the
animal industry.
Clostridium perfringens. Clostridium perfringens is an anaerobic Gram-positive sporeforming rod that is widely distributed in the environment. It is frequently found in the intestines
of humans and animals, and its spores persist in soils. This species is not a strict anaerobe and
can tolerate some exposure to oxygen (Pearson, 1976).
The organisms are classified on their ability to produce certain types of toxins (types A,
B, C, D, and E). Perfringens food poisoning is caused by type A strains. Gas gangrene strains
are also of this type (Jay, 1996). Foods associated with this illness are meats, meat products,
gravy, and dried or precooked foods (CDC, 2001). It has been found on 66% of fresh pork
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products (NRC, 1999). Infective dose is high (approximately 108 viable cells) (Shandera et al.,
1983). Symptoms appear 8-12 hours after consumption and include intense abdominal cramps
and diarrhea. The illness runs its course usually within 24 hours (Schlossberg, 2001).
The illness is relatively mild and the true incidence of perfringens poisoning is unknown.
It is estimated that 250,000 cases occur annually, and is one of the most commonly reported
foodborne illnesses. Hospitalization and death rarely occur (Mead, 1999).
Ingested microbes produce enterotoxin in the intestine, and the toxin binds to intestinal
epithelial cells. Binding is specific and leads to damaged host cell membranes which alters
permeability properties. Glucose absorption is inhibited, while sodium and chloride ions are
secreted (McDonel, 1980). For the farmer, decreased nutrient uptake means reduced feed
efficiency. Eliminating C. perfringens from the intestines would improve growth performance
(Strauch, 1987c). Another concern to poultry farmers is necrotic enteritis caused by type A or
type C strains, which can lead to high mortality within a flock (Porter, 1998).
Antibiotic resistance increases the chance of survival and decreases elimination of the
pathogen from the gastrointestinal tract. Tetracycline resistance is found on a conjugative
plasmid and expression can be induced by exposure to subinhibitory levels of the antibiotic
(Johanesen et al., 2001). Tetracycline and macrolide-lincosamide resistance in C. perfringens
has been correlated to antimicrobials fed to pigs (Rood et al., 1985).
Treatment of bacterial foodborne gastroenteritis. Gastroenteritis is considered selflimited and usually does not require medical attention. However, it is recommended that a
physician be consulted if there is fever, bloody stools, significant abdominal pain, dehydration,
or risk factors. Treatment may include rehydration and administration of agents to control
diarrhea. Treatment for specific microbes will depend on the clinical situation and/or
identification of the pathogen. The latter requires time for growth of the organism. Often,
empiric antibiotic therapy with a quinolone is prescribed before a complete diagnosis is made
(Schlossberg, 2001). Without confirmation of a specific microbe and its resistance patterns,
antibiotic treatment may create complications or increase severity of disease, such as prolonged
diarrhea or HUS.
Risk factors for patients include age and disease state. Populations including the elderly,
the very young, and patients recently treated with antibiotics are more susceptible to infection.
Their intestinal flora is altered and the risk of gastroenteritis is increased. Populations with
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compromised immune systems including the elderly, the very young, and people with certain
diseases (i.e., AIDS and cancer) are more susceptible to complications (Schlossberg, 2002). A
list of antibiotic treatments for foodborne illnesses can be found in Table 2.
Antibiotic use in food animals (meat and dairy) has implications for treatment of all
bacterial infections, not just foodborne illnesses. Approved antibiotics used to treat infections in
food animals include ampicillin, amoxicillin, erythromycin, oleandomycin, tetracyclines,
gentamicin, streptomycin, penicillin, lincomycin, neomycin, spectinomycin, sulfonamides, and
fluoroquinolones. Penicillin, ampicillin, some tetraclyclines, and oleandomycin are all approved
for use to improve growth and feed efficiency. Some antibiotics (erythromycin and penicillin)
are available over the counter and do not require a prescription from a veterinarian (NRC, 1999).
All of the above mentioned antibiotics are used to treat a variety of human illnesses
(Schlossberg, 2001).
Recall that resistance may develop to antibiotics in the same class. Although tetracycline
may not be used for growth promotion, its derivatives (chlortetracycline and oxytetracycline) are
used, and resistance to one can infer resistance to the other (Rood et al., 1985). The use of
virginiamycin as a growth promoter selects for resistant Enterococcus faecium and
staphylococci, and can confer cross-resistance to streptogramins used for human therapy (SCAN,
1998b). The use of tylosin and spiramycin as growth promoters can result in cross-resistance to
erythromycin in Gram-positive and Gram-negative bacteria (SCAN, 1998a). Avilamycin is used
as a growth promoter in swine and poultry, and has been linked to decreased sensitivity to
evernimomicin, which has been under development for human use. Both compounds have the
same mode of action (SCAN, 2000).
Reducing the Development and Spread of Antibiotic Resistance
There are several approaches to addressing the increasing problem of antibiotic resistant
microorganisms. Each has advantages and disadvantages. Some proposed solutions only side
step the true problem. Others are more difficult to achieve, but have positive and lasting results.
Nevertheless, steps must be taken to prevent a post-antibiotic era. As previously discussed,
pathogens not only become non-responsive to antibiotics, but their virulence may increase and
severity of disease may intensify.
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Table 2. Antibiotic therapy for food-borne gastroenteritis.a
Bacteria

Preferred

Alternatives

Salmonella
typhimurium

Ciprofloxacin or
Ceftriaxoneb

Chloramphenicol,
Amoxicillin or TMPSMXc,d

Campylobacter
jejuni

Erythromycin

Ciprofloxacin,
Aminoglycosides,
Chloramphenicol

EIEC, ETEC,
EPECe

Quinolonef

TMP-SMX, double
strength

Comments

Antibiotic therapy is
not recommended for
EHEC strains
Antibiotic treatment not
recommended

Clostridium
perfringens
a

Table adapted from Scholssberg, D., ed., 2001. Current Therapy of Infectious Disease.
Ceftriaxone is a third-generation cephalosporin.
c
TMP-SMX = trimethoprim-sulfamthoxazole.
d
Amoxicillin or TMP-SMX treatment for neonate or immunocompromised child only after
patient is stable and susceptibility data is known.
e
EIEC = enterinvasive E. coli, ETEC = enterotoxogenic E. coli, EPEC = enteropathogenic E.
coli, EHEC = enterohemorrhagic E. coli.
f
Quinolone oral therapy options include ciprofloxacin, ofloxacin, and levofloxacin.
b
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Discovery and creation of new antibiotics. A temporary solution is the discovery or
creation of new antibiotics. Bacteria that were once difficult to grow in the laboratory can now
be cultivated courtesy of newer, more successful culturing methods (Kaeberlein et al, 2002).
When newly discovered bacteria are studied, chemicals they produce are also studied. In some
cases, these chemicals are unique and may be antimicrobial in nature. Well-studied bacteria or
fungi may also produce novel antimicrobials. A strain of the bacterium Bacillus cereus isolated
from soil was found to produce a bacteriocin (a miniature protein) that inhibited the growth of
pathogens and food spoilage bacteria (Bizani and Brandelli, 2002). Plus, scientists are constantly
creating synthetic antibiotics and finding new drug targets (Silver and Bostian, 1993).
One advantage to this approach is good response to treatment. When new antibiotics are
introduced effectiveness to treat or prevent disease in humans is very successful at first. When
penicillin was first introduced it was considered a miracle drug and prevented many deaths due
to common infections (Levy, 1992). However, microbes have the genetic ability to develop
resistance quickly to any antimicrobial introduced. When penicillin resistance became prevalent
in Staphylococcus aureus, methicillin became the drug of choice to treat infections. Only two
years after being introduced, methicillin-resistant S. aureus (MRSA) isolates were discovered in
the United Kingdom (Jevons, 1961). This led to the use of vancomycin to treat MRSA
infections, and now vancomycin-resistant S. aureus strains have emerged (Sieradzki et al., 1999;
Smith et al., 1999). Emerging resistance to antibiotics applies to other pathogens as well, such as
Streptococcus pneumoniae, Enterococcus species, E. coli, and Klebsiella pneumoniae
(Georgopapadakou, 2002).
Altering the use of antibiotics in human therapy. Antibiotics will always maintain a
place in the treatment and prevention of diseases. Notwithstanding, there are circumstances
where non-use of antibiotics is appropriate. Each year, millions of antibiotics are prescribed for
colds, upper respiratory tract infections, and bronchitis (Gonzales et al., 1997). Antibiotics are
only effective for treating bacterial or fungal infections and have little to no effect on these
common ailments. Physicans’ habits and pressure from patients cause over-prescription and lead
to misuse resulting in antibiotic resistance (Williams and Heymann, 1998).
In Hungary in the 1980’s, penicillin was cheap and overuse led to 50% of pneumococcus
infections reported as penicillin resistant. By 1992, resistant infections were down by 16%. This
occurred in part because physicians changed prescribing habits, relying on other classes of non-
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β-lactam antibiotics (Nowak, 1994). This suggests that rotational use of antibiotics could
alleviate some resistance problems.
Empiric antibiotic therapy is when antibiotics are administered early in an illness prior to
culture identification and clinical response. These antibiotics are generally broad-spectrum,
meaning they are active against a wide range of organisms. Conversely, narrow-spectrum drugs
may target a specific genus or species of microbe (Conte, 2002). If the illness is caused by an
antibiotic resistant strain, certain empiric antibiotics might not be appropriate. One author
suggests that doctors use surveillance to make an educated decision on which antibiotic therapy
to administer. Setting up surveillance systems could provide information to support decisions
based on level of resistance in geographical regions as well as changes in the level of resistance.
A web-based searchable database would provide doctors quick and easy access to this
information (Felmingham, 2002).
Finally, a hospital in Finland was able to eliminate 10 strains of MRSA and prevent the
spread of nosocomial (hospital acquired) MRSA infections. This was accomplished through
strict and aggressive control measures. MRSA-positive patients were treated in contact isolation,
and staff was intensively educated on hospital hygiene (Kotilainen et al, 2003).
Altering the use of antibiotics in livestock. There is without question a link between
antibiotic use in livestock and antibiotic resistant bacteria affecting humans. Growing concerns
were voiced by the Swann Committee in England in a 1969 report (Swann, 1969). The World
Health Organization (WHO, 1997) and the United States Food and Drug Administration (FDA,
2000) have also reported possible medical risks resulting from the use of antimicrobials in
animal feeds. The conclusions of these reports call for the limited use and elimination of
antibiotics as growth promoters in animal feeds. More recently, Engberg et al. (2001) tracked
macrolide and quinolone resistance emergence in Campylobacter species. They concluded that
quinolone resistance in humans frequently coincides with or follows the approval of
fluoroquinolone (a type of quinolone) use in livestock.
Several countries have already taken steps towards eliminating antibiotics as growth
promoters. The European Union (EU) includes 15 member countries and 13 other eastern and
southern European countries preparing for accession. The Council of the Union has passed
several directives concerning additives in feedstuffs. The first Council Directive was passed in
1970 (EC, 1970). Since then there have been numerous amendments and regulations passed into
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law (EC, 1994). Additives, including antibiotics, are authorized for a limited time and must be
re-evaluated and re-authorized for continued use. Re-authorization requires the company to
prove efficacy and safety. The additive must improve the feedstuffs or livestock without causing
harm to the environment, animals, or humans. Harm includes development of antibiotic
resistance to a particular antibiotic used in human medicine, or the development of crossresistance to other antibiotics used in human medicine. The EU has already banned avoparcin
(EC, 1997), bacitracin zinc, spriramycin, virginiamycin, and tylosin phosphate (EC, 1998a) due
to antibiotic resistance. Carbadox and oliquindox were banned due to genotoxic, carcinogenic,
and tumorigenic properties (EC, 1998b). The remaining growth promoting antibiotics
flavophospholipol (flavomycin), salinomycin sodium, lasalocid sodium, and monensin sodium
are being re-evaluated (EC, 2002).
While some antibiotic resistant genes will remain in the environment, there is evidence
that resistance levels decrease after withdrawal of antibiotics in animal feeds. Some resistance is
acquired through chromosomal mutation, as previously discussed. This mutation puts a strain on
the cell and is conditional on continued growth under antibiotic pressure. When antibiotic
pressure is removed, resistance may return to low levels. This has been shown for tetracycline
and chloramphenicol resistance in E. coli (George and Levy, 1983). However, even with
removal of antibiotics, low levels of resistance may remain. Low-level resistance is a precursor
in adaptive evolution towards high-level, clinical resistance (Baquero, 2001). For example, a
combination of low-level antibiotic resistance mechanisms may have a synergistic, additive
effect resulting in high-level resistance.
The other method of resistance is through mobile genetic elements such as plasmids,
transposons, integrons, and phages as previously discussed. One study has shown that exposure
to antibiotics increases transfer rate of plasmids encoding antibiotic resistance in Bacteriodes
species found in the human colon (Stevens et al., 1992). By removing antibiotic pressure there is
less of a need for microbes to develop and/or transfer antibiotic resistance genes. Linton (1976)
observed a decline in resistant E. coli isolated from swine feces after the removal of an antibiotic
(aureomycin) from drinking water. Resistance declined from 90% resistant isolates at 93 days
prior to slaughter to 35% on the day of slaughter. Resistance was attributed to transferable
plasmids. In another study, six months after the removal of tetracycline from a chicken farm,
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there was a reversal in selection for resistant organisms in human farm residents’ fecal flora.
Resistant bacteria contained transferable plasmids (Levy et al., 1976).
Alternatives to antibiotics. Animals carry bacteria in their feces and may contaminate
carcasses, passing the organisms onto the meat products, and finally to the consumer. Bacteria
that develop antibiotic resistance in the animal may also follow this route. If the resistant
bacteria are pathogens, severe or untreatable illness may occur. Reducing pathogens in the
animal decreases the chance of carcass contamination and illness in humans. However,
antibiotic resistant bacteria may not be eliminated in animals by sub-therapeutic levels of
antibiotics. Carcass contamination is unavoidable, but there are alternatives to antibiotics for the
purpose of growth promotion in livestock. These alternatives can be used to prevent
development and spread of antibiotic resistance as well as decrease the number of diseasecausing organisms in livestock.
Animals that become stressed have a tendency to developed stress-related illnesses.
Causes of stress include large numbers of animals of different origins in confined spaces, poor
hygiene, climate conditions, and raising leaner but heavier animals. Sub-therapeutic levels of
antibiotics are often fed to prevent stress-related illnesses. Reducing stress and/or replacing
antibiotics with alternatives can eliminate the need for growth promoting antibiotics. A German
study concluded that a homeopathic mixture of herbs and minerals was more effective at
preventing diseases of the respiratory tract in pigs than sub-therapeutic levels of antibiotics
(Albrecht and Schütte, 1999).
A probiotic is a “live microbial feed supplement which beneficially affects the host by
improving its intestinal microbial balance” (Fuller, 1989). Probiotics include many bacterial
species and some fungi. Probiotics are associated with improved performance and reduction of
disease. Piglets fed 106-107 viable spores of Bacillus lichenformis or Bacillus cereus var. toyoi
exhibited reduced incidence and severity of diarrhea, significantly lowered mortality, and
increased performance compared to negative controls (Kyriakis et al, 1999). In another study,
piglets with rotavirus and E. coli associated diarrhea were fed 109 cfu/piglet/day (colony forming
units per pig per day of Bifidobacterium lactis (Shu et al., 2001). The probiotic group exhibited
reduced severity of diarrhea, increased performance, and lower concentrations of fecal rotavirus
and E. coli compared to negative controls. Probiotics may also have a direct effect on the host’s
intestinal morphology and mucins (Baum et al., 2002).
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A prebiotic is a “non-digestible food ingredient that beneficially affects the host by
selectively stimulating the growth and/or activity of one or a limited number of bacteria in the
colon” (Gibson and Roberfroid, 1995). Prebiotics include non-digestible but fermentable
carbohydrates (oligo- and polysaccharides), some proteins, and certain lipids. The goal is to
stimulate growth of advantageous bacteria (bifidobacteria and lactobacilli) while suppressing
adverse bacteria (pathogens). In one study, rats fed resistant potato starch had stimulated growth
of bifidobacteria (Kleessen et al., 1997). Another study indicated that swine treated with
fructooligosaccharides in their drinking water had reduced fecal shedding of S. typhimurium
(Letellier et al., 2000).
Food ingredients may be classified as a probiotic or prebiotic. Probiotic bacteria are used
in cheeses, yogurts, sausages, and fermented milk. Dietary fiber is considered a prebiotic and is
found in many foods of plant origin. Other ingredients may also have beneficial health effects.
Phytochemicals are biologically active plant chemicals. For example, the anti-cancer compound
lycopene is found in tomatoes (Love et al., 2000). Collectively, any food or food ingredient that
may provide a health benefit beyond the traditional nutrients it contains can be called a
“functional food” (Thomas and Earl, 1994). A variety of foods have anti-cancer properties,
including soy, flaxseed, tomatoes, garlic, broccoli, tea, fish, dairy products, and beef (Hasler,
1998).
There are several terms used in the United States today to describe specific categories of
foods (Table 3). The definitions often overlap and it can be difficult to categorize some
particular foods. Currently, herbs are not considered foods or drugs, but “dietary supplements”
by the Food and Drug Administration (DSHEA, 1994). However, in other countries such as
Germany, herbs are considered to be drugs and are strictly controlled by the government
(Blumenthal, 1998). In this text, functional foods and herbs will be considered separate
categories, but collectively will be referred to as foods unless specifically noted.
Studies of foods in livestock diets are limited. There is some information available on
clinical studies in humans, but studies on the effect of animal performance and gut microbiology
are few. In some farming districts of Australia, it is a common practice to add raspberry juice or
raspberry cordial (35% pure fruit juice) to the drinking water of livestock and humans (Ryan et
al., 2001). This practice is thought to prevent or cure the symptoms of gastroenteritis. However,
there is little to no scientific evidence to support this claim. Ryan et al. (2001) demonstrated the
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Table 3. Definitions of food terms.
Term
Dietary
Supplement

Definition
A product (other than tobacco) that is intended to
supplement the diet that bears or contains one or more
of the following dietary ingredients: a vitamin, a
mineral, an herb or other botanical, and amino acid, a
dietary substance for use by man to supplement the
diet by increasing the total daily intake, or
concentrate, metabolite, constituent, extract, or
combinations of these ingredients….is intended for
ingestion in pill, capsule, tablet, or liquid form….is
not represented for use as a conventional food.

Reference
DSHEA, 1994

Food

Any raw, cooked, or processed edible substance, ice,
beverage, or ingredient used or intended for use or for
sale in whole or in part for human consumption, or
chewing gum.

FDA, 1999

Functional
food

Any food or food ingredient that may provide a health
benefit beyond the traditional nutrients it contains.

Thomas and
Earl, 1994

Herb

A plant or plant part that is used to make medicine,
food flavors (spices), or aromatic oils for soaps and
fragrances.

Strohecker,
1994

Medical food

A food which is formulated to be consumed or
administered enterally under the supervision of a
physician and which is intended for the specific
dietary management of a disease or condition for
which distinctive nutritional requirement on the basis
of recognized scientific principles are established by
medical evaluation.

U. S. Congress,
1988

Nutraceutical

Any substance that may be considered a food or part
of a food and provides medical or health benefits,
including the prevention and treatment of disease.

Love et al.,
2000

Prebiotic

Non-digestible food ingredient that beneficially affects
the host by selectively stimulating the growth and/or
activity of one or a limited number of bacteria in the
colon.

Gibson and
Roberfroid,
1995

Probiotic

Live microbial feed supplement which beneficially
affects the host by improving its intestinal microbial
balance.

Fuller, 1989
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antimicrobial nature of raspberry juice and cordial, inhibiting Gram-negative and Gram-positive
pathogens.
Echinacea (purple coneflower) is an herb that can increase immune function (Rehman et
al., 1999). One study demonstrated that inclusion of 3% echinacea in swine diets resulted in
improved feed efficiency and daily gain compared with 0 or 1.5% echinacea. Daily gain of the
pigs on the 3% diet was also equal to the control diet containing the growth promoter carbadox
(Holden and McKean, 2000).
Advantages and Disadvantages of Functional Foods and Herbs
There are advantages and disadvantages to inclusion of food into livestock diets. Each
must be studied before decisions are made, and the benefits must outweigh the risks. Scientific
research must come first, followed by education of the community, then implementation on the
farm.
Foods are not regulated as drugs are, and do not have to go through a lengthy approval
process (NRC, 1999). Implementation of foods and herbs into the diet can begin without a
waiting period. They can be readily available in mass quantities. They are also considered a
“natural” alternative, which is becoming an increasing public demand.
Another problem is acceptance of new ideas by profit driven industries. Pharmaceutical
companies would lose revenue from loss of antibiotic sales. Plus, farmers are leery of
implementing new ideas. Antibiotics are confirmed to improve livestock performance. Studies
have shown a 33 to 75% improvement in growth compared to non-antibiotic supplementation
(Hays and Speer, 1960). The difference in percentages was due to environment. Cleaner
conditions and healthier animals resulted in a smaller response to antibiotics. Other studies
under experimental conditions have also shown growth improvement due to antibiotic
supplementation (Cromwell, 2001).
A food must be proven to improve performance without side effects. Ephedra is an herb
considered to be a dietary supplement and is not strictly regulated by the FDA. It is used to
encourage weight loss or increase energy performance of athletes. This herb has been linked to
stroke, heart disease, and sudden death (Samenuk et al., 2002). Garlic has been the subject of
many studies and is thought to have multiple health benefits (Amagase et al., 2001). Yet, when
included in a swine diet, animals had decrease performance and extremely objectionable off-
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flavors in the meat (Holden et al., 1998). Animal studies must be done in order to get a true
sense of the effects on treatment and prevention of diseases, growth performance, and quality of
the final product.
It is more costly to raise livestock without the use of growth promoting antibiotics
(Larson and Kliebenstein, 2002). This does not take into account replacing antibiotics with
alternatives. More importantly, it does not include the human cost of antibiotic resistance and
the ability to effectively prevent and treat disease. Drugs of first choice are abundant and
relatively cheap. If the first round of therapy is ineffective, a more costly drug might be the
alternative choice (Conte, 2002). In extreme cases, the cost is loss of life due to an untreatable
disease.
Another dilemma involves standardization. What are the active compounds in the food?
How do they benefit the animal? What level of the compound is required in order to see a
beneficial result? Are the levels consistent between cultivars? Many factors can affect the
chemical composition of foods. Some herbal supplement companies impose standardization of
active ingredients on their own products (Ternus, 1999).
A major group of biologically active ingredients in plants is phenolic compounds
(Shahidi and Naczk, 1995). These phytochemicals contain at least one aromatic (benzene) ring
with one or more hydroxyl groups (OH) attached. Other compounds may also be attached
(Figure 2). Level of phenolics may change depending on environmental conditions or plant
cultivar.
Growing and harvesting conditions will have an affect on chemical composition. What
type of soil is the plant grown in, and does is contain the proper nutrients? What are the weather
conditions, has there been a drought, a late freeze, or ideal conditions? Geographic location can
dictate soil type and climate to some degree. Crop load will affect chemical composition. High
yielding apple trees have been shown to have smaller, less colorful fruits. Lower crop loads
resulted in increased quality and higher phenolic concentrations in Jonagold Apples (Stopar et
al., 2002). Maturity at harvest plays a role. Broccoli and cauliflower harvested from 3-day-old
sprouts had higher concentrations of anticancer compounds compared to mature plants (Fahey et
al., 1997).
Stress can cause chemical changes in plants. Physical stresses can occur from harvesting
or insect infestation, and biological stresses can occur from fungal, bacterial, or viral infection.
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Figure 2. Benzene ring and phenolic compounds.
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Phenolic compounds are a main defense chemical in many plants (Shahidi and Naczk, 1995).
Stress response results in an increase in total phenolics content (Rhodes and Wooltorton, 1978).
Food processing can cause chemical changes. Thermally processed tomatoes into paste
resulted in a decrease of the anti-cancer compound lycopene (Takeoka et al., 2001). Increased
cooking time and presence of skin increased phenolic content of peach puree without affecting
quality (Talcott et al., 2000).
Regardless, active ingredients must be studied in the test tube (in vitro) and in living
systems (in vivo) to get a complete picture of how a food is functional. Phenolic compounds are
a very active group of phytochemicals and have been found to have antimicrobial, antioxidant,
and anticarcinogenic activities. Phenolics extracted from the herb Scrophularia inhibited both
Gram-positive and Gram-negative bacteria including Bacillus subtilis, Staphylococcus aureus, E.
coli, S. typhimurium and Moraxella lacunata (Fernández et al., 1996). A direct relationship
between antioxidant activity and total phenolic content of various vegetables, fruits, and herbs
has been demonstrated (Velioglu et al., 1998). However, composition of the phenolics was
different depending on plant type and was a factor in level of antioxidant activity. Antioxidant
activity has been linked to anticarcinogenic properties due to the ability of phenolics to prevent
DNA damage (Lodovici et al., 2001).
Caffeic Acid and Chlorogenic Acid
Some of the most common phenolic compounds found in foods of plant origin are the
hydroxycinnamic acids (HCA), also called phenolic acids (Kroon and Williamson, 1999). HCAs
contain at least one cinnamic acid and at least one –OH group (Figure 3). In particular, two
prevalent HCAs are caffeic acid (CFA) and chlorogenic acid (CGA).
Caffeic acid is the simplest of the HCAs, bearing only a simple cinnamic acid group and
two -OH groups (Figure 3). It has been found in numerous foods, including cereals, legumes,
oilseeds, fruits, vegetables, herbs, and beverages (Table 4). CFA is the predominant HCA in
most fruits (Shahidi and Naczk, 1995).
Caffeic acid has been shown to have antioxidant activities. Oxidative damage is caused
by free radicals. Metal ions can initiate the formation of free radicals. CFA is able to chelate
(bind) iron (Fe2+) due to its hydroxyl groups (Kono et al., 1998) and has also been shown to
chelate copper (Cu2+) and scavenge free radicals (Nardini et al., 1995). In the latter study, CFA
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Cinnamic Acid
Coumaric Acid

Caffeic Acid

Chlorogenic acid

Figure 3. Cinnamic and hydroxycinnamic acids.
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Table 4. Caffeic acid and chlorogenic acid content of selected foods and beverages.
Chlorogenic
Acid
173 mg/kg

Reference

Food/beverage

Caffeic Acid

Apples

85-1270 mg/kg

Artichoke

219 mg/kg

Radtke et al., 1998

Barley

7.0-18 mg/kg

Hernanz et al., 2001

Beer, German

1 mg/L

Shahidi and Nazck,
1995

Blueberry

977 mg/kg

Broccoli

19 mg/kg

Radtke et al., 1998

Brussel sprouts

34 mg/kg

Stich, 1991

Carrot, orange

85 mg/kg

Alasalvar et al., 2001

Carrot, purple

24 mg/kg

Cherry, sour

121 mg/kg

Coffee

631 mg/kg

Corn

4.5 mg/kg

Echinacea purpurea
(herb)

125 mg/kg

Eggplant

330 mg/kg

Radtke et al., 1998

Endive

284 mg/kg

Radtke et al., 1998

Grapefruit

40 mg/kg

Radtke et al., 1998

Kiwi

384 mg/kg

Radtke et al., 1998

Lettuce

160-900 mg/kg

Stich, 1991

Oats

1-5 mg/kg

Shahidi and Naczk,
1995

1851-2075 mg/kg

541 mg/kg

Stich, 1991
van der Sluis et al., 2001

Radtke et al., 1998
Schuster and Herrmann,
1985

Alasalvar et al., 2001
Radtke et al., 1998

1300 mg/L

Radtke et al., 1998
Stich, 1991
Shahidi and Naczk,
1995

320 mg/kg
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Głowniak et al., 1996

Table 4 (continued)
Peach

159 mg/kg

Pear

77 mg/kg

Plum

110 mg/kg

Potato

Radtke et al., 1998
18-141 mg/kg

Raktke et al., 1998
Amiot et al., 1995
Raynal et al., 1989

96-187 mg/kg

Friedman, 1997

411-436 mg/kg

Donovan et al., 1998

Prune

9-10 mg/kg

Sorghum

6.0-8.7 mg/kg free
17-45 mg/kg bound

Shahidi and Naczk,
1995

Strawberries

15-39 mg/kg

Stich, 1991

Sunflower, meal

0.2%

Tea

250 mg/kg

Tea, fennel

2.7%

Cater et al., 1972
Stich, 1991

560-1000 mg/kg

Bilia et al., 2000

Tomato

24 mg/kg

Radtke et al., 1998

Wine, red

6-13 mg/L

Frankel et al., 1995

Wine, white

1-4 mg/L

Frankel et al., 1995
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inhibited the oxidation of low-density lipoproteins (LDL), which is linked to atherosclerosis and
heart disease.
CFA has been the focus of several antimicrobial studies. It has shown significant growth
inhibition of C. perfringens without inhibiting Bifidobacter and Lactobacillus (Lee et al., 2001).
Studies have shown inhibited growth of E. coli and K. pneumoniae at 300 ppm and the fungus
Aspergillus at 200 ppm, and completely inhibited aflatoxin production at 200 ppm (Aziz et al.,
1998). The inhibitory activity was attributed to presence of –OH groups. E. coli O157:H7 and
S. typhimurium were also inhibited by 350 ppm CFA using an agar dilution method (Tunel and
Nergiz, 1993). Staphylococcus aureus, Bacillus subtilis, and the yeast Candida albicans were
inhibited at 200 ppm, while Cornybacterium diptheria, Aspergillus niger, Aspergillus flavus, and
Pullularia pullularis were inhibited by 100 ppm of CFA (Binutu et al., 1995). Studies vary on
whether CFA is an effective inhibitor of Gram-negative organisms. Regardless, phenolic content
of some foods may affect survivability of Gram-negative pathogens. CFA in apple juice had a
concentration dependent affect on the survival of E. coli O157:H7 (Reinders et al., 2001).
Antiviral activity against Vesicular Stomatitis Virus (VSV) has also been reported at the level of
500 ppm CFA (Cheminat et al., 1988).
Chlorogenic acid is made up of two subunits, caffeic acid and quinnic acid (Figure 3).
These subunits are released with hydrolysis. CGA is the most abundant soluble form of HCAs in
the diet (Faulds and Williamson, 1999) and is thought to be the source of dietary CFA (Kroon
and Williamson, 1999). CGA has been found in many of the same foods as caffeic acid (Table
4). CGA is also an antioxidant, with the same mechanisms as CFA (Kono et al., 1998). It has
been shown to inhibit DNA damage due to oxidation (Kasai et al., 2000) and prevent colon
cancer in rats (Mori et al., 2000). One study suggests its usefulness for controlling glucose levels
in non-insulin-dependent diabetes (Hemmerle et al., 1997). CGA also has antimicrobial activity,
though it is less studied than CFA. Shigella sonnei (Group D) was 78% inhibited by 400 µM of
CGA (approximately 145 ppm; Tsou et al., 2000).
Influence of Diet on Health
The microbial ecology of an animal’s gastrointestinal tract is a major factor in
maintaining animal health. The natural flora in the intestine helps animals resist infections by
competing with pathogens (Fuller, 1989). Volatile fatty acids (VFAs) are produced as a result of

31

microbial carbohydrate fermentation in the gut, and are absorbed and used as a source of energy
in the large intestine of non-ruminants (Wolin, 1981). Diet composition greatly influences the
microbial balance (Varel et al., 1984; Varel et al., 1987), and therefore influences disease
resistance and available energy. Studying the effect of diet on microbial populations can be
accomplished by studying live animals (in vivo), or environments in a test tube that mimic real
life situations (in vitro). Studies on whole foods may provide an overall picture. However, in
order to know specifically which phytochemicals have an effect, individual compounds must be
studied separately.
Many species of animals are used to produce meat or dairy products. Pork consumption
accounts for 40% of the annual total world consumption of meat (Pond and Lei, 2000).
Improving growth characteristics are a main concern for farmers. However, studying swine may
have human health implications. Despite some differences, pigs have an omnivorous digestive
system similar to humans. Anaerobic fermentation of fiber and VFA production are comparable,
and pig models are often used to predict what might happen in humans (Pond and Lei, 2000).
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CHAPTER 3
Methods Development
Introduction
Certain aspects of this study required preliminary work prior to the main projects.
Particular details of established and standard methods did not work upon first or second attempts.
This required that the methods be adjusted slightly in order to achieve repeatable results before
conducting the main study. The major factor was media composition.
Study 1. Aerobic Culture Growth in Ethanol
Introduction
The minimum inhibitory concentrations (MICs) of antimicrobial compounds on the
growth of aerobic cultures were tested using the macrobroth dilution method as previously
described (NCCLS, 2000). This method required that the compounds be solubilized in broth
used to grow the bacteria. The compounds used in this study, caffeic acid (CFA) and
chlorogenic acid (CGA) were not water soluble. CFA and CGA were previously reported to be
freely soluble in alcohol (Budavari, 1989), and therefore the broth was reformulated to contain a
specific amount of alcohol. Ethanol is lethal to aerobic bacteria in high concentrations. The
objective of this preliminary study was to determine the ability of aerobic cultures to survive and
grow in broth containing low concentrations of ethanol.
Materials and Methods
Media
Mueller-Hinton Broth (MHB; Difco Laboratories, Detroit, MI) was mixed with distilled
water, 10.3 mL (10 mL after autoclaving) distributed into tubes, and autoclaved for 10 min at
121°C.
Ethanol (95%) was cold sterilized using a sterile Swinnex-25 syringe apparatus
(Millipore Corporation, Bedford, MA) containing an Isopore™ membrane filter with 0.2µm pore
size (Millipore). The volume of several MHB tubes were averaged and used as a base to
determine the amount of filtered 95% ethanol to be aseptically added to achieve a final
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concentration of 3% ethanol in the MHB tubes. An aliquot (330 µL) of 95% ethanol was added
for every 10 mL MHB.
Bacterial cultures and conditions
Cultures tested were Staphylococcus aureus ATCC 12600, S. aureus ATCC 25923, S.
aureus ATCC 27543, S. aureus ATCC 43300, Escherichia coli ATCC 11775, E. coli ATCC
25922, E. coli 25404, E. coli 43895, Salmonella enteritidis 108A (University of Kentucky Food
Science stock culture), Salmonella choleraesuis subsp. choleraesuis (Smith) Weldin serotype
Typhimurium ATCC 13311, S. choleraesuis subsp. choleraesuis (Smith) Weldin serotype
Typhimurium ATCC 700408, and Salmonella sp. TT42 (University of Kentucky Food Science
stock culture isolated from swine feces).
Frozen stock cultures were transferred twice into MHB and incubated at 35°C for 24 hr.
Cultures were checked for purity, transferred to MHB containing 3% ethanol, and incubated in
the same conditions. The controls contained MHB with no ethanol. Presence or absence of
growth was visually observed at 24 hr and compared to controls.
Results and Discussion
Two of the bacteria tested, S. enteritidis 108A and E. coli ATCC 25404, were inhibited
by ethanol (growth was less than 0.125 McFarland). None of the other cultures were affected by
the addition of 3% ethanol, and growth was comparable to the control with no ethanol (growth
was >0.5 McFarland).
It is important when testing the MIC of a compound to eliminate possible interference.
First, susceptibility cannot be reliably determined unless there is adequate growth. Ethanol
inhibited growth of the two bacterial cultures, and it would not be possible to determine whether
CFA or CGA would inhibit growth. Therefore, the two bacteria inhibited by 3% ethanol were
removed from further MIC testing.
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Study 2. Compound and Agar Component Interaction
Introduction
The MICs of antimicrobial compounds on the growth of anaerobic cultures were to be
tested using the agar dilution method as previously described (NCCLS, 2001). This method calls
for the use of a supplemented blood agar for the testing of the compounds. A previous study
showed that Clostridium perfringens ATCC 13124 was inhibited by 0.1 mg (100 µg) of CFA
using a disk diffusion method (Lee et. al., 2001). Another study indicated that C. perfringens
ATCC 3624 was inhibited by 500 ppm (500 µg/mL) of CFA using a broth dilution method
(Debrauwer, et. al., 1989). In this study, 1000 ppm of CFA failed to inhibit C. perfringens
ATCC 13124 and C. perfringens 92D.
Other studies have shown that CFA and CGA can chelate iron (Kono et. al., 1998) and
bind to hemoglobin (Suryaprakash et. al., 2000). The objective of this preliminary study was to
determine which component of the supplemented blood agar was interacting with the compounds
and interfering with the testing.
Materials and Methods
Antimicrobial compound
A 10 mg/mL stock solution of CFA (Sigma-Aldrich, St. Louis, MO) was solubilized in
70% ethanol and stirred with a magnetic stir bar for 5 min with gentle heating (40°C). Ethanol
solution was prepared using distilled water. A final concentration of 1000 ppm was achieved by
adding 2 mL of CFA stock solution into 18 mL of medium.
Media
Mueller-Hinton broth was mixed with distilled water, distributed into tubes, and
autoclaved at 121°C for 10 min. Brucella broth (BB; Difco) was mixed with distilled water,
distributed into tubes, and autoclaved at 121°C for 15 min. Brucella broth plus 0.16% agar was
prepared by mixing with distilled water, supplemented with 1.6 g/L granulated agar (Difco),
distributed into tubes, and autoclaved at 121°C for 15 min.
Cooked Meat Medium (CM; Difco) was distributed (1.25 g) into tubes and 10 mL of
distilled water was added. Medium was allowed to sit for 10 min at room temperature before
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autoclaving at 121°C for 15 min. If medium was not used within 24 hr, tubes were steamed for
an additional 10 min and cooled just before use.
Mueller-Hinton Agar (MHA; Difco) and Brucella Agar (BA; Difco) were mixed with
distilled water, steamed, and autoclaved at 121°C for 15 min.
Vitamin K1 Brucella Agar (v-BA) was prepared by the addition of 5 mg/L vitamin K1
(Sigma-Aldrich) to BA as previously described (NCCLS, 2001). Vitamin K1 (3phytylmenadione) stock solution was prepared by adding 0.2 mL to 20 mL of 95% ethanol and
stored at 4°C for no longer than one year. Vitamin K1 working solution was prepared by adding
1 mL of stock solution to 9 mL of sterile distilled water, and stored at 4°C for no longer than 1
month. Brucella Agar was mixed with distilled water, supplemented with 1 mL/L vitamin K1
working solution, and autoclaved at 121°C for 15 min.
Hemin Brucella Agar (h-BA) was prepared by the addition of 1 mg/L hemin (SigmaAldrich) to BA as previously described (NCCLS, 2001). Hemin stock solution was prepared by
dissolving 0.1 g into 2 mL of 1.0 N NaOH (Fisher Scientific, Fairlawn, NJ), the volume brought
up to 20 mL with distilled water, and sterilized at 121°C for 15 min. Hemin was protected from
light by wrapping the bottle in aluminum foil and stored at 4°C for no longer than 1 month.
Brucella Agar was mixed with distilled water, supplemented with 1 mL/L hemin stock, and
autoclaved at 121°C for 15 min.
Supplemented Brucella Agar (s-BA) was prepared by the addition of 5 mg/mL vitamin
K1 and 1 mg/mL hemin. Brucella Agar was mixed with distilled water, supplemented with 1
mL/L vitamin K1 working solution and 1 mL/L hemin stock solution, and autoclaved at 121°C
for 15 min.
Supplement Brucella Blood agar (s-BBA) was prepared by the addition of 5%
defribrinated laked sheep blood (Gibson Laboratories, Lexington, KY) to sterile s-BA as
previously described (NCCLS, 2001). Blood and autoclaved agar were tempered to 48°C before
the addition of 5% blood.
All tested agar media was distributed in 18.2 mL aliquots (to achieve 18 mL after
autoclaving) into 50-mL polypropylene BlueMax™ Falcon® conical tubes (Becton Dickinson
Labware, Franklin Lakes, NJ). The media was autoclaved for 15 min at 121°C. After cooling to
48°C, either 2 mL of CFA stock solution plus 1 mL sterile distilled water, 2 mL CFA stock
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solution plus 1 mL sheep blood, or 2 mL 70% ethanol plus 1 mL sterile distilled water (controls)
were added and mixed gently. Contents of the tube were poured into a sterile 15 x 100 mm
round petri plate (Fisherbrand; Fisher) and allowed to solidify. Agar plates were placed in a
35°C incubator with lids ajar for 30 min to dry and were prepared on the day of inoculation.
Bacterial cultures and conditions
Isolates tested were S. aureus ATCC 12600, S. aureus ATCC 25923, S. aureus ATCC
27543, S. aureus ATCC 43300, C. perfringens 92D (University of Kentucky isolate from
poultry), C. perfringens ATCC 13124, and Campylobacter jejuni ATCC 33291.
Staphylococcus aureus cultures were transferred twice into MHB and incubated at 35°C
for 24 hr. Cultures were then streaked onto MHA and incubated at 35°C for 24 hr. Typical
colonies were selected and suspended in MHB broth until 0.5 McFarland standard was achieved.
Cultures were then spotted (2 µL) onto the various agars containing CFA or ethanol and
incubated for 48 hr. Agars tested included MHA, RCM, BA, v-BA, h-BA, s-BA, and s-BBA.
All incubations for C. perfringens cultures were in Gas-Pak Anaerobic System jars with
CO2 System Envelopes (BBL, Sparks, MD) at 35°C for 24 hr. Cultures were transferred twice
into CM. Cultures were then streaked onto s-BBA and incubated. Typical colonies were
selected and suspended in Brucella broth until 0.5 McFarland standard was achieved. Cultures
were then spotted (2 µL) onto the various agars containing CFA or ethanol and incubated for 48
hr. Agars tested included MHA, RCM, BA, v-BA, h-BA, s-BA, and s-BBA.
Incubations for C. jejuni were in a Gas Pak jar with Campylobacter System Envelopes
(BBL) at 42°C for 48 hr. The culture was transferred twice in BB plus 0.16% agar. Cultures
were then streaked onto s-BBA and incubated. Typical colonies were selected and suspended in
BB until 0.5 McFarland standard was achieved. Cultures were spotted (2 µL) onto agars
containing CFA or ethanol. Agars tested included MHA, RCM, BA, v-BA, h-BA, s-BA, and sBBA.
Results and Discussion
Binutu et al. (1995) had previously found that S. aureus was inhibited by CFA using an
agar dilution method. In this study, S. aureus cultures were used as an aerobic control using an
agar method. The cultures were inhibited by 1000 ppm CFA on MHA.
37

A summary of results can be found in Table 5. Caffeic acid was effective at inhibiting
growth of both C. perfringens cultures at the level of 1000 ppm on MHA, BA, h-BA, v-BA, and
s-BA. Supplementation with vitamin K1 had no effect on the availability of CFA and did not
interfere with antimicrobial action. The addition of hemin to the agar also did not interfere with
the antimicrobial action. The structure of hemin contains an iron atom, which is covalently
bound to four nitrogen atoms surrounded by four pyrrole rings linked by methene bridges (Figure
4). The iron in hemin is also bound to a chloride atom. Although CFA and CGA can chelate
iron, the iron atom in hemin is not available to interact with the compounds. However, free iron
and hemoglobin proteins are abundant in blood and were available to bind to CFA (Nilsson et al.,
2002; Moran et al., 1994a). This binding interfered with the ability of CFA to prevent microbial
growth. The use of blood in agar dilution medium formulations was discontinued in all other
tests.
Growth of C. perfringens was not supported on RCM containing CFA or on the control
containing 7% ethanol. None of the media tested supported the growth of C. jejuni. The lack of
growth could have been due to the high level of ethanol combined with type of media used.
Study 3. Media Combinations
Introduction
Results from Study 2 indicated that C. perfringens and C. jejuni growth was not
supported on certain agars. The agars contained 7% ethanol and might have influenced growth.
Also, Stern et. al. (1988) concluded that combinations of source and growth medium influenced
the effect of antimicrobial compounds. The objective of this study was to determine which
combination of media best encouraged C. perfringens and C. jejuni growth.
Materials and Methods
Media
Brucella Agar (BA; Difco) was mixed with distilled water and autoclaved at 121°C for
15 min. Cooked Meat Medium (CM; Difco) was distributed (1.25 g) into tubes and 10 mL of
distilled water was added. Medium was allowed to sit for 10 min at room temperature before
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Table 5. Summary of results from Study 2a.

MHA

S. aureus ATCC 25923
S. aureus ATCC 27543
S. aureus ATCC 12600
S. aureus ATCC 43300
C. perfringens 92D
C. perfringens ATCC 13124
C. jejuni ATCC 33291

1000 ppm
CFA
-

RCM

C. perfringens 92D
C. perfringens ATCC 13124
C. jejuni ATCC 33291

-

-

BA

C. perfringens 92D
C. perfringens ATCC 13124
C. jejuni ATCC 33291

-

+
+
-

h-BA

C. perfringens 92D
C. perfringens ATCC 13124
C. jejuni ATCC 33291

-

+
+
-

v-BA

C. perfringens 92D
C. perfringens ATCC 13124
C. jejuni ATCC 33291

-

+
+
-

s-BA

C. perfringens 92D
C. perfringens ATCC 13124
C. jejuni ATCC 33291

-

+
+
-

s-BBA

C. perfringens 92D
C. perfringens ATCC 13124
C. jejuni ATCC 33291

+
+
-

+
+
-

Medium

Isolate

a

Ethanol
Control
+
+
+
+
+
+
-

MHA = Mueller-Hinton Agar, BA = Brucella Agar, h-BA = hemin supplemented Brucella
Agar, v-BA = vitamin K1 supplemented Brucella Agar, s-BA = hemin and vitamin K1
supplemented Brucella Agar, s-BBA = hemin and vitamin K1 supplemented Brucella Blood
Agar. Agars contained either 1000 ppm caffeic acid (CFA) or 7% ethanol. (+) indicates growth,
(-) indicates no growth.
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Figure 4. Structure of hemin.
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autoclaving at 121°C for 15 min. If medium was not used within 24 hr, tubes were steamed for
an additional 10 min and cooled just before use.
Reinforced Clostridial Medium (RCM; Difco) was mixed with distilled water,
supplemented with 15 g/L granulated agar, and autoclaved at 121°C for 15 min. A final
concentration of 1.5% agar was achieved in the medium.
Figures 5 and 6 illustrate the different combinations tested. Agar plates containing 3.5%
ethanol were prepared by the addition of 1 mL of 70% ethanol to tubes containing 19 mL sterile,
tempered (48°C) agar. Agar plates containing 7% ethanol were prepared by the addition of 2 mL
of 70% ethanol to tubes containing 18 mL sterile, tempered agar. Plates were dried and as
previously described.
Bacterial cultures and conditions
All incubations for C. perfringens were incubated in anaerobic Gas-Pak jars at 35°C for
24 hr unless otherwise stated. Initially, C. perfringens ATCC 13124 and C. perfringens 92G
were streaked onto s-BBA, BA, and RCM containing no ethanol and growth was observed after
48 hr. Stock cultures were transferred twice into CM and incubated. Cultures were then
streaked onto the appropriate agar. After incubation, typical colonies were selected and
suspended in BB until 0.5 McFarland standard was achieved. Cultures were then spotted (2 µL)
onto the various agars containing ethanol and incubated for 48 hr.
All incubations for C. jejuni were in a microaeophilic incubator (5% O2, 10% CO2) for 48
hr at 42°C. Initially, C. jejuni ATCC 33291 was streaked onto s-BBA, BA, and MHA containing
no ethanol and growth was observed after incubation. The stock culture was transferred twice in
BB plus 0.16% agar and incubated. The culture was then streaked onto the appropriate agar.
After incubation, typical colonies were selected and suspended in BB until 0.5 McFarland
standard was achieved. Cultures were then spotted (2 µL) to achieve a final inoculum of 2 x 105
bacteria onto the various agars containing ethanol and incubated.
Results and Discussion
A summary of results can be found in Table 6. Clostridium perfringens growth was
supported on s-BBA, BA, and RCM containing no ethanol. Growth was inhibited on all agars
containing 7% ethanol. Most of the agars containing 3.5% ethanol only supported the growth of
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Clostridium perfringens
stock culture
Cooked Meat Medium
Cooked Meat Medium
s-BBA

BA

RCM

0.5 McFarland standard
in Brucella Broth

0.5 McFarland standard
in Brucella Broth

0.5 McFarland standard
in Brucella Broth

BA + 3.5% EtOH

BA + 3.5% EtOH

BA + 3.5% EtOH

BA + 7% EtOH

BA + 7% EtOH

BA + 7% EtOH

RCM + 3.5% EtOH

RCM + 3.5% EtOH

RCM + 3.5% EtOH

RCM + 7% EtOH

RCM + 7% EtOH

RCM + 7% EtOH

Figure 5. Flow chart of Clostridium perfringens for Study 3. s-BBA = supplemented
Brucella Blood Agar, BA = Brucella Agar, RCM = Reinforced Clostridial Medium plus 1.5%
agar, EtOH = ethanol, % EtOH represents total amount of ethanol in 20 mL agar plate.
Incubations for transfers and initial agars were anaerobic at 35°C for 24 hours. Incubations for
plates with ethanol were 48 hours.
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Campylobacter jejuni
stock cultures
Brucella Broth
plus 0.16% agar
Brucella Broth
plus 0.16% agar

s-BBA

BA

MHA

0.5 McFarland standard
in Brucella broth

0.5 McFarland standard
in Brucella broth

0.5 McFarland standard
in Brucella broth

BA + 3.5% EtOH

BA + 3.5% EtOH

BA + 3.5% EtOH

BA + 7% EtOH

BA + 7% EtOH

BA + 7% EtOH

MHA + 3.5% EtOH

MHA + 3.5% EtOH

MHA + 3.5% EtOH

MHA + 7% EtOH

MHA + 7% EtOH

MHA + 7% EtOH

Figure 6. Flow chart of Campylobacter jejuni in Study 3. s-BBA = supplemented Brucella
Blood Agar, BA = Brucella Agar, MHA = Mueller-Hinton Agar, EtOH = ethanol, % EtOH
represents total amount of ethanol in 20 mL agar plate. All incubations were in a
microaerophilic incubator (5% O2, 10% CO2) at 42°C for 48 hours.
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Table 6. Summary of results for Clostridium perfringens cultures from Study 3a.
Source Agar
s-BBA

BA

RCM

Growth Agar

Isolate

Growth

BA + 3.5% EtOH

C. perfringens ATCC 13124
C. perfringens 92D

+

BA + 7% EtOH

C. perfringens ATCC 13124
C. perfringens 92D

-

RCM + 3.5% EtOH

C. perfringens ATCC 13124
C. perfringens 92D

+

RCM + 7% EtOH

C. perfringens ATCC 13124
C. perfringens 92D

-

BA + 3.5% EtOH

C. perfringens ATCC 13124
C. perfringens 92D

+
+

BA + 7% EtOH

C. perfringens ATCC 13124
C. perfringens 92D

-

RCM + 3.5% EtOH

C. perfringens ATCC 13124
C. perfringens 92D

+

RCM + 7% EtOH

C. perfringens ATCC 13124
C. perfringens 92D

-

BA + 3.5% EtOH

C. perfringens ATCC 13124
C. perfringens 92D

+
+

BA + 7% EtOH

C. perfringens ATCC 13124
C. perfringens 92D

-

RCM + 3.5% EtOH

C. perfringens ATCC 13124
C. perfringens 92D

+

RCM + 7% EtOH

C. perfringens ATCC 13124
C. perfringens 92D

-

a

s-BBA = supplemented Brucella Blood Agar, BA = Brucella Agar, RCM = Reinforced
Clostridial Medium plus 1.5% agar, EtOH = ethanol. (+) indicates growth, (-) indicates no
growth.
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C. perfringens ATCC 13124, but did not support the growth of C. perfringens 92D. Only two
combinations, BA from BA and BA from RCM, were able to support the growth of both
cultures.
The NCCLS (2001) standard for testing MICs with anaerobic cultures using the agar
dilution method requires 2 mL of the selected compound be added to each agar plate. Recall that
the compounds used in this project are solubilized with 70% ethanol. This results in 7% ethanol
in the final agar. Because this will not support culture growth, a lower concentration for further
MIC testing was used. A volume of 1 mL of the compound results in 3.5% ethanol in the final
agar. This concentration supported the growth of C. perfringens cultures and therefore the
standard method was adjusted. Brucella Agar from RCM containing 3.5% ethanol was used for
further MIC testing for C. perfringens cultures.
Campylobacter jejuni growth was supported on s-BBA, BA, and MHA containing no
ethanol. However, growth on MHA was minimal, and it was difficult achieving 0.5 McFarland
needed for inoculation. There was no growth on any of the agars containing 3.5% or 7% ethanol.
These percentages were too high to support growth.
Study 4. Ethanol and Campylobacter jejuni Growth
Introduction
Results from Study 3 revealed that C. jejuni cultures did not grow on any of the agar
plates tested. This was attributed to amount of ethanol in the agar. The objective of this study
was to determine what ethanol concentrations would allow the growth of C. jejuni.
Materials and Methods
Antimicrobial compounds
In order to achieve no more than 1.5% ethanol in the final media, a limit of 30% ethanol
was set for solubility of the compounds. Caffeic acid stock solutions of 64 and 48 mg were
mixed in 3 mL of distilled water. Seventy percent ethanol was added by 0.5 mL aliquots until
the set limit was reached. Stock solutions were stirred with a magnetic stir bar for 5 min with
gentle heating (40°C). Final concentrations of 640 and 480 ppm were achieved by adding 1 mL
of CFA stock solution into 19 mL of medium.
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Chlorogenic acid stock solutions of 64 and 48 mg were mixed with 3 mL distilled water.
Ninety-five percent ethanol was added in 0.5 mL aliquots until CGA was solubilized. In
addition, a CGA stock solution of 80 mg/mL was mixed with 4 mL of distilled water. Seventy
percent ethanol was added by 0.5 mL aliquots until CGA was solubilized. Stock solutions were
stirred with a magnetic stir bar for 5 min with gentle heating. Final concentrations of 800 and
600 ppm were achieved by adding 1 mL of CGA stock solution into 19 mL of medium.
Media
Brucella Agar was mixed with distilled water and distributed in 19.2 mL aliquots (to
achieve 19 mL after autoclaving) into 50-mL polypropylene BlueMax™ Falcon® conical tubes.
The media was autoclaved for 15 min at 121°C. After cooling to 48°C, 1 mL of CFA stock
solution, 1 mL of CGA stock solution, or 1 mL of 30% ethanol (controls) was added and mixed
gently. Contents of the tube were poured into a sterile 15 x 100 mm round petri plate and
allowed to solidify. Agar plates were placed in a 35°C incubator with lids ajar for 30 min to dry
and were prepared on the day of inoculation.
Bacterial culture and conditions
Campylobacter jejuni ATCC 33291 was incubated in a microaerophilic incubator (5%O2,
10% CO2) at 42°C for 48 hr. Stock culture was transferred twice in BB plus 0.16% agar and
incubated. The culture was then streaked onto s-BBA. After incubation, typical colonies were
selected and suspended in BB until 0.5 McFarland standard was achieved. The culture was then
spotted (2 µL) onto BA containing 1 mL of the stock solution, 1 mL of 30% ethanol, or 1 mL
sterile distilled water as previously described and incubated.
Results and Discussion
Campylobacter jejuni growth was supported agar plates containing 1.5% ethanol and was
comparable to growth on agar plates with no ethanol. Agar dilution plates containing 1.5%
ethanol will be used for future MIC testing.
Chlorogenic acid went into solution at a concentration of 16 mg/mL in 14% ethanol. A
volume of 1 mL was added to an agar plate for a final concentration of 800 ppm CGA and 0.7%
ethanol. Growth was not inhibited.
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Chlorogenic acid also went into solution at 16 and 12 mg/mL in 23% ethanol. A volume
of 1 mL was added to agar plates for final concentrations of 800 and 600 ppm with 1.15% total
ethanol. Growth was not inhibited.
Caffeic acid was not soluble at 12.8 and 9.6 mg/mL in 28% ethanol. A volume of 1 mL
was added to agar plates for a final concentration of 640 and 480 ppm with 1.4% total ethanol.
Despite the visible insolubility, CFA inhibited growth at 480 ppm.
The difference in the solubility of CFA and CGA lies in their structures (Figures 7 and 8).
Chlorogenic acid includes a quinnic acid moiety and is more hydrophilic than CFA. This
accounts for the ability of CGA to go into solution at a much lower ethanol percentage.
Therefore, when conducting MICs, the solubility of CFA combined with the inability of C. jejuni
to survive on agar containing ethanol are limiting factors.
Study 5. Compound Solubility
Introduction
There were two limiting factors for MIC testing of CFA on C. jejuni using the agar
dilution method. First, C. jejuni did not grow on agar dilution medium containing more than
1.5% ethanol. Second, CFA was not soluble in some in ethanol/water mixtures. The highest
concentration used for MIC testing was 1000 ppm. In order to achieve a maximum of 1.5%
ethanol and 1000 ppm CFA in the agar dilution medium, the following combinations for CFA
stock solutions would be required:
1) For 2 mL of stock solution into 18 mL agar, 10 mg/mL CFA in 15% ethanol
2) For 1 mL of stock solution into 19 mL agar, 20 mg/mL CFA in 30% ethanol
3) For 0.5 mL of stock solution into 19.5 mL agar, 40 mg/mL CFA in 60% ethanol
However, Study 4 demonstrated that 9.6 and 12.8 mg/mL CFA were not soluble in 28% ethanol.
This excluded options 1 and 2 for the stock solution. Therefore, the objective of this study was
to determine if 40 mg/mL CFA would solubilize in 60% ethanol.
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Figure 7. Structure of caffeic acid (3,4-dihydroxycinnamic acid).
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Figure 8. Structure of chlorogenic acid (5-caffeoylquinic acid).
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Materials and Methods
Ethanol/water mixture was prepared with distilled water to achieve a 60% ethanol
solution. Caffeic acid stock solution was prepared by the addition of 40 mg/mL CFA to 60%
ethanol. The stock solution was stirred using a magnetic stir bar for 10 min with gentle heating.
Results and Discussion
Caffeic acid was soluble at the concentration of 40 mg/mL in 60% ethanol. Therefore,
concentrations of less than 40 mg/mL CFA will also solubilize in 60% ethanol. This meets the
requirements of 1.5% ethanol and 1000 ppm solubilized CFA or less in agar dilution medium. In
this study, it was determined that distribution of 0.5 mL stock solution (60% ethanol) into 19.5
mL agar dilution medium was optimal for MIC testing of CFA on C. jejuni.
Study 6. In Vitro Survival of Campylobacter jejuni
Introduction
Initially, a main objective was set to determine the effect of CFA and CGA on survival of
C. jejuni for an in vitro study using swine feces. However, the inoculated culture did not survive
the incubation period. Because a minimal medium was used, it was thought that the culture
could not survive in that particular medium. Thus, the objective of this study was to determine if
C. jejuni cultures would survive the incubation period in a minimal medium.
Materials and Methods
Media
Phosphate and magnesium chloride dilution water was prepared as previously described
(Marshall, 1992). Stock phosphate solution was prepared by dissolving 34 g KH2PO4 (Fischer)
in 500 mL distilled water, pH adjusted to 7.2 with 1 N NaOH, the volume brought up to 1 L with
distilled water, and sterilized at 121°C for 15 min. Stock MgCl2 solution was prepared by
dissolving 38 g MgCl2 (Sigma-Aldrich) in 1 L distilled water, and autoclaved at 121°C for 15
min. Stock solutions were stored at 4°C until use. Class C dilution water was prepared by the
addition of 1.25 mL stock phosphate solution and 5 mL MgCl2 solution, and the volume brought
up with distilled water to 1 L. The pH was adjusted to 7.4 (pH 7.2 after autoclaving). Media
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was dispensed in aliquots of 10.2 mL into tubes or 105 mL into bottles (to achieve 9.9 and 99
mL blanks after autoclaving, respectively). Dilution blanks were then autoclaved for 15 or 30
min at 121°C for tubes or bottles, respectively. Brucella stearothermophilus spores, BT Sure
biological indicator for steam sterilization (Barnstead/Thermolyne, Inc., Dubuque, IA), was used
as an indicator of sterility. Spores were autoclaved with the media then incubated at 55°C for 24
hrs. Lack of growth indicated the autoclave was working properly.
Anaerobic dilution solution was prepared according to methods previously described
(Holdeman and Moore, 1975). The salts solution contained 0.2 g/L anhydrous CaCl2 (J. T. Baker
Chemical Company, Phillipsburg, NJ), 0.2 g/L MgSO4•7H2O (Sigma-Aldrich), 1 g/L K2HPO4
(Fischer), 1 g/L KH2PO4, 10 g/L NaHCO3 (Fisher), and 2 g/L NaCl (Fischer). Salts were
dissolved in distilled water. For each liter of media, 500 mL of distilled water was combined
with 2 g/L gelatin (Difco), 1 mL resazurin solution, and 500 mL of salt solution. Resazurin
(Sigma-Aldrich) solution was prepared by dissolving 100 mg in 100 mL distilled water. The
medium was boiled then cooled, and 5 g/L L-cysteine (Sigma-Aldrich) was added under a
constant flow of CO2 using gas jets. Medium continued under a flow of CO2 until it turned from
pink to colorless. A volume of 50 mL was anaerobically transferred into a 125-mL serum bottle
under a flow of CO2. The bottle was sealed by a butyl rubber stopper and crimp-sealed. The rest
of the medium was transferred to the anaerobic chamber for fecal processing. The anaerobic
chamber was under a CO2 environment in the absence of O2.
Campylobacter Agar Base (Karmali; Oxoid, Hampshire, England) was mixed with
distilled water and sterilized at 121°C for 15 min. Sterile agar was tempered to 48°C and
supplemented with freeze-dried Campylobacter Selective Supplement SR167E (Karmali;
Oxoid). One vial of supplement contained 50 mg sodium pyruvate, 16 mg cefoperazone, 10 mg
vancomycin, and 50 mg cyclohexamide. Vial components were dissolved by 2 mL of 50%
ethanol and aseptically added to every 500 mL of sterile Karmali Agar. Karmali agar was used
for the enumeration of Campylobacter coli and C. jejuni at 42°C.
Fecal samples
Swine feces were collected from a Duroc X Landrace/Yorkshire crossbred barrow. The
animal was 4 months of age, weighed 60 kg, and was housed at the University of Kentucky
Animal Laboratory. The diet consisted of 82% corn, 16% dehulled soybean meal, 1% dicalcium
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phosphate, and less than 1% of lysine, limestone, salt, vitamin and mineral mix, and 0.05%
Tylan-40. Pigs were kept in individual 5’ x 10’ pens with slatted floors, continuous lighting, and
a constant temperature of approximately 25°C. Water was available ad libitum. A fresh stool
sample was obtained, placed in a plastic bag, and delivered into the anaerobic chamber within 10
min of collection for processing. Anaerobic chamber was under a CO2 environment in the
absence of O2.
Fresh feces (10 g) was blended with 100 mL anaerobic dilution solution in a Waring
blender for 60 seconds to achieve a 10% (w/v) fecal slurry. The slurry (50 mL) was transferred
into a 125-mL serum bottle under a constant flow of CO2. The bottle was sealed by a butyl
rubber stopper and crimp-sealed.
Bacterial culture and conditions
Campylobacter jejuni ATCC 33291 was transferred twice in BB plus 0.16% agar and
incubated microaerophilically at 42°C for 48 hr. The culture was streaked onto s-BBA and
incubated for another 48 hr in the same conditions. Colonies were suspended in sterile dilution
water until 0.5 McFarland Standard was achieved. An inoculum amount of 1 mL was
anaerobically transferred to serum bottles containing anaerobic dilution solution or fecal slurry.
Serum bottles were incubated in a shaking water bath at 125 rpm for 24 hr at 39°C. Initial slurry
and final samples were diluted using sterile dilution water, and 0.1 mL was plated using the
spread plate method onto Karmali agar. Plates were incubated in a microaerophilic incubator
(5% O2 and 10% CO2) at 42°C for 48 hr.
Results and Discussion
A summary of results can be found in Table 7. Bacterial counts for the initial slurry and
slurry at 24 hr were comprised of both C. jejuni and Campylobacter coli. Karmali agar supports
the growth of both organisms for these incubation conditions. Without further testing, it is not
possible to distinguish between these two species.
Bacterial counts for the medium containing only the C. jejuni inoculum after 24 hr had
good survival. The counts were reduced by only 10% (less than 101 CFU/mL). On the other
hand, when feces were added to the combination, survival was drastically reduced. The counts
were diminished by 64% (104 CFU/mL). The pH did not drop after 24 hr, and a pH of 6.5 is well
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Table 7. In vitro survival of Campylobacter jejuni in mediuma with and without feces.
CFU/mLc

pH

Initial fecal slurryb

1.7 x 105

Medium plus inoculumd
at 24 hours

4.5 x 105

6.5

2 x 102

6.5

Fecal slurry plus inoculumd
at 24 hours
a

Medium consisted of anaerobic dilution solution.
Fecal slurry was 10% (w/v) feces (wet weight) in the medium.
c
CFU/mL = colony forming units per milliliter.
d
Inoculum was C. jejuni ATCC 33291 at the level of 2 x 106 bacteria/mL.
b
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within the range for supporting Campylobacter survival (optimum pH of 7.0). Campylobacter
requires 5-10% oxygen; yet, they can survive, but not grow, under reduced-oxygen conditions
(BAM, 2001). However, the microbial population of swine feces is very diverse and
competitive. This particular environment may introduce too much competition for C. coli and C.
jejuni to survive and grow.
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CHAPTER 4
Minimum Inhibitory Concentrations of
Caffeic Acid and Chlorogenic Acid and Their Effect on
the Microbial Ecology of Swine Feces In Vitro
Introduction
Preliminary work in Chapter 3 described adjustments to established and standard
methods needed to complete this study. These adjustments involved formulation changes to the
different media types.
The first objective of this study was to determine the Minimum Inhibitory Concentrations
(MICs) of caffeic acid and chlorogenic acid against potential pathogens. The MIC is the
minimal concentration of an antimicrobial required to inhibit or kill a microorganism (Murray,
1995). This information is useful when studying specific compounds and specific
microorganisms. It may also provide clues as to how an antimicrobial will affect overall
microbial ecology.
The second objective was to determine the effect of caffeic acid and chlorogenic acid on
the fecal microbial population of swine. In vitro studies can offer a general look at the microbial
population without the use of live animals. In vitro studies sustain a more controlled and
uniform environment compared to using a number of different animals. While this provides
invaluable information, all aspects must be considered.
Materials and Methods
Minimum Inhibitory Concentration
Antimicrobial compounds. Caffeic acid (CFA; Sigma-Aldrich, St. Louis, MO) and
chlorogenic acid (CGA; Sigma-Aldrich) were tested at the levels of 0, 50, 100, 200, 300, 400,
500, 600, 800, and 1000 ppm. CFA and CGA were solubilized in 70% ethanol and stirred with a
magnetic stir bar for 5 min with gentle heating (40°C). A stock solution of 20 mg/mL was
prepared and a portion was diluted with 70 % ethanol by a 1:2 ratio to achieve a solution of 10
mg/mL. A stock solution of 16 mg/mL was prepared and a portion was diluted with 70% ethanol
in a series of 1:2 ratios to achieve concentrations of 8 mg/mL, 4 mg/mL and 2 mg/mL. Finally, a
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stock solution of 12 mg/mL was prepared and a portion was diluted with 70% ethanol by a 1:2
ratio to achieve 6 mg/mL solution. For the testing of Campylobacter jejuni, CFA and CGA were
solubilized and diluted in 60% ethanol. Ethanol solutions were prepared using distilled water.
For aerobic cultures, stock solutions were filter sterilized using a sterile Swinnex-25
syringe apparatus (Millipore Corporation, Bedford, MA) containing an Isopore™ membrane
filter with 0.2µm pore size (Millipore).
Media. Brain Heart Infusion Broth (BHI; Difco Laboratories, Detroit, MI) was mixed
with distilled water, 6 mL distributed into tubes, and autoclaved for 15 min at 121°C. Brucella
broth (BB; Difco) was mixed with distilled water, 10 mL were distributed into tubes, and
autoclaved at 121°C for 15 min. Brucella broth plus 0.16% agar was prepared by the addition of
1.6 g/L granulated agar (Difco), mixed with distilled water, 10 mL distributed into tubes, and
autoclaved for 15 min at 121°C. Reinforced Clostridial Medium (RCM; Difco) plus 1.5% agar
was prepared by the addition of 15 g/L granulated agar and mixed with distilled water before
autoclaving at 121°C for 15 min.
Cooked Meat Medium (CM; Difco) was distributed (1.25 g) into tubes and 10 mL of
distilled water added. Medium sat for 10 min at room temperature prior to autoclaving at 121°C
for 15 min. If the medium was not used within 24 hr, tubes were steamed for an additional 10
min and cooled just before use.
Mueller-Hinton Broth (MHB, Difco) was mixed with distilled water. For culture growth
tubes, 10 mL were distributed into tubes and autoclaved for 10 min at 121°C. For the
macrobroth dilution tubes used for the testing of Minimum Inhibitory Concentrations (MICs) of
aerobic cultures, 200 mL MHB were distributed into bottles and autoclaved for 10 min at 121°C.
Then, 0.9 mL of sterile medium was aseptically transferred to sterile 13 x 100 glass tubes in
order to avoid inconsistent volumes from autoclaving. The tubes were incubated at 25°C
overnight to verify sterility. The CFA and CGA stock solutions were prepared, as described, and
0.1 mL was aseptically added to each sterile 13 x 100 broth tube on the day of inoculation.
Agar dilution plates for testing the Minimum Inhibitory Concentration (MIC) on
Clostridium perfringens cultures contained Brucella Agar (BA; Difco). The medium was mixed
with distilled water and distributed in 19.2 mL aliquots (to achieve 19 mL after autoclaving) into
50-mL polypropylene BlueMax™ Falcon® conical tubes (Becton Dickinson Labware, Franklin
Lakes, NJ). The medium was autoclaved for 15 min at 121°C, cooled to 48°C, and 1 mL of CFA
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or CGA stock solution was added and mixed gently. Contents of the tube were poured into a
sterile 15 x 100 mm sterile round petri plate (Fisherbrand, Fischer Scientific, Fairlawn, NJ) and
allowed to solidify. Agar plates were placed in a 35°C incubator with lids ajar for 30 min to dry
and were prepared on the day of inoculation.
Agar dilution plates for the MIC of Campylobacter jejuni contained Supplemented
Brucella Agar (s-BA). The medium was prepared by the addition of 1 mg/L hemin and 5 mg/L
vitamin K1 to BA as previously described (NCCLS, 2001). Hemin (Sigma-Aldrich) stock
solution was prepared by dissolving 0.1 g into 2 mL of 1.0 N NaOH (Fisher), the volume brought
up to 20 mL with distilled water, and sterilized at 121°C for 15 min. Hemin was protected from
light by wrapping aluminum foil around a dark glass bottle and stored at 4°C for no longer than 1
month. Vitamin K1 (3-phytylmenadione; Sigma-Aldrich) stock solution was prepared by adding
0.2 mL to 20 mL of 95% ethanol and stored at 4°C for no longer than one year. Vitamin K1
working solution was prepared by adding 1 mL of stock solution to 9 mL of sterile distilled
water, and stored at 4°C for no longer than 1 month. Brucella Agar was supplemented with 1
mL/L hemin stock and 1 mL/L vitamin K1 working solution. Supplemented Brucella Agar was
distributed in 19.8 mL aliquots (to achieve 19.5 mL after autoclaving) into 50-mL polypropylene
BlueMax™ Falcon® conical tubes and autoclaved. Agar was cooled to 48°C and 0.5 mL of
CFA or CGA stock solution was added and mixed gently. Contents of the tube were poured into
a 15 x 100 mm sterile round petri plate and allowed to solidify. Agar plates were placed in a
35°C incubator with lids ajar for 30 min to dry and were prepared on the day of inoculation.
Supplement Brucella Blood agar (s-BBA) was prepared by the addition of 5%
defribrinated laked sheep blood (Gibson Laboratories, Lexington, KY) to sterile s-BA as
previously described (NCCLS, 2001). After autoclaving, blood and agar were tempered to 48°C
prior to addition of 5% blood. Plates were allowed to solidify and dried for 30 min at 35°C in an
incubator with lids ajar. Unused plates were stored at 4°C for no longer than 48 hr. Blood was
stored at 4°C for no longer than 1 month.
Bacterial Cultures and Conditions. A complete list of bacterial strains tested is
presented in Table 8. Aerobic cultures, including Salmonella, Escherichia coli, and
Staphylococcus aureus were tested for susceptibility using the macrobroth dilution method as
previously described (NCCLS, 2000). Frozen stock cultures were transferred into Brain Heart
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Table 8. List of bacterial strains used for Minimum Inhibitory Concentration testing.
Strain

Source

Incubation conditions

Campylobacter jejuni subsp.
jejuni ATCCa 33291

Human feces

Microaerophilicb, 42°C, 48
hrs

Clostridium perfringens
ATCC 13124

Quality control strain,
produces α-toxin

Anaerobic, 35°C, 24 hrs

Clostridium perfringens
(92D)

University of Kentucky
isolate from poultry

Anaerobic, 35°C, 24 hrs

Escherichia coli
ATCC 11775
Escherichia coli
ATCC 25922

Urine

Aerobic, 35°C, 24 hrs

Clinical isolate

Aerobic, 35°C, 24 hrs

Escherichia coli O157:H7
ATCC 43895

Hamburger

Aerobic, 35°C, 24 hrs

Salmonella choleraesuis
subsp. choleraesuis (Smith)
Weldin serotype
Typhimurium
ATCC 13311

Food Poisoning in Man

Aerobic, 35°C, 24 hrs

Salmonella choleraesuis
subsp. choleraesuis (Smith)
Weldin serotype
Typhimurium,
ATCC 700408

Phage type DT104,
multi-drug resistant

Aerobic, 35°C, 24 hrs

Salmonella sp. (TT42)

University of Kentucky
isolate from swine feces

Aerobic, 35°C, 24 hrs

Staphylococcus aureus
ATCC 12600

Pleural fluid

Aerobic, 35°C, 24 hrs

Staphylococcus aureus
ATCC 25923

Clinical isolate

Aerobic, 35°C, 24 hrs

Staphylococcus aureus
ATCC 27543

Mastitic cow

Aerobic, 35°C, 24 hrs

Clinical isolate,
Staphylococcus aureus
Aerobic, 35°C, 24 hrs
ATCC 43300
methicillin resistant
a
ATCC = American Type Culture Collection.
b
Microaerophilic conditions were 5% O2, 10% CO2, 85% N2.
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Infusion broth (BHI, Difco) and incubated 24 hr at 35°C. Cultures were checked for purity,
transferred to fresh BHI broth, and incubated 8 hr. Cultures were transferred into MHB
containing 3% ethanol, and incubated for 24 hr at 35°C. After incubation, cultures were
transferred to MHB and adjusted to 0.5 McFarland standard. One mL of culture was then
transferred into macrobroth dilution tubes containing MHB and CFA or CGA, and incubated 24
hr at 35°C.
Clostridium perfringens cultures were tested using the agar dilution method for
susceptibility of anaerobic bacteria according to NCCLS standards (NCCLS, 2001). All
incubations were in anaerobic Gas-Pak jars (BBL, Sparks, MD) using CO2 system envelopes
(BBL) for 24 hr at 35°C. Frozen stock cultures were transferred twice in CM. The cultures were
then streaked onto RCM containing 1.5% agar. After incubation, typical colonies were selected
and suspended in BB until 0.5 McFarland standard was achieved. Cultures were then spotted (2
µL) onto BA containing various concentrations of CFA and CGA stock solutions and incubated
for 48 hr. Hemin, vitamin K1, and blood were not added to the agar dilution plates used for
susceptibility testing.
Campylobacter jejuni was tested using the agar dilution method for susceptibility of
anaerobic bacteria according to NCCLS standards (NCCLS, 2001). All incubations were in a
microaerophilic incubator (5% O2, 10% CO2) at 42°C for 48 hr. Frozen stock was transferred
twice into in BB plus 0.16% agar, and then streaked onto s-BBA. Typical colonies were selected
and suspended in BB until 0.5 McFarland standard was achieved. Cultures were spotted (2 µL)
onto s-BA containing various concentrations of CFA and CGA stock solutions and incubated.
Blood was not added to the agar dilution plates used for susceptibility testing.

In Vitro Incubation
Media. A complete list of media used is in Table 9. Anaerobic dilution solution was
prepared according to methods previously described (Holdeman and Moore, 1975). The salts
solution contained 0.2 g/L anhydrous CaCl2 (J. T. Baker Chemical Company, Phillipsburg, NJ),
0.2 g/L MgSO4•7H2O (Sigma-Aldrich), 1 g/L K2HPO4, 1 g/L KH2PO4, 10 g/L NaHCO3, and 2
g/L NaCl (Fisher Scientific). Salts were dissolved in distilled water. For each liter of media, 500
mL of distilled water was combined with 2 g/L gelatin (Difco), 1 mL resazurin solution, and 500
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Table 9. Complete list of media and their use in this study.
Media

Target Culture and
Incubation Conditions

Purpose

Anaerobic Dilution Solutiona In vitro incubation

Fecal microflora, shaking
water bath, 125 rpm, 39°C
for 24 hrs

BS-LVb

Enumeration

Bifidobacteria, anaerobic,
37°C for 72 hrs

Brain Heart Infusion broth
(BHI)c

Enrichment

S. aureus, E. coli, S.
enteritidis, S. typhimurium,
Salmonella sp., 35°C for 8
or 24 hrs

Brucella Agar (BA)c

Agar dilution susceptibility
testing

C. perfringens, anaerobic,
35°C for 48 hrs.

Brucella Broth (BB)c

0.5 McFarland standard for
agar dilution testing

C. perfringens, C. jejuni, no
incubation

Coliform/E. coli Petrifilmd

Enumeration/
Differentiation

E. coli, coliforms, 35°C for
24 hrs

Cooked Meat Mediumc

Enrichment

C. perfringens, anaerobic,
35-37°C, 24 hrs

Granulated Agarc

Supplement to RCM and
Brucella Broth

C. perfringens, Total
Anaerobes, C. jejuni

Karmali Agar (KA)e

Enumeration

C. jejuni and C. coli,
microaerophilic, 42°C for
72 hrs

Mueller-Hinton Broth
(MHB)c

Enrichment, 0.5 McFarland
standard for macrobroth
dilution testing

S. aureus, E. coli, S.
enteritidis, S. typhimurium,
Salmonella sp., 35°C for 24
hrs

OPSPe

Enumeration

C. perfringens, anaerobic,
37°C for 72 hrs

Phosphate and Magnesium
Chloride Dilution Waterf

Dilution blanks

All, no incubation
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Table 9 (continued)
Reinforced Clostridial
Mediumc with 1.5% agar
(RCM)

Enrichment

C. perfringens, anaerobic,
35-37°C for 24 hrs

Reinforced Clostridial
Medium with 1.5% agar

Enumeration

Total Anaerobic count,
anaerobic, 37°C for 72 hrs

Rogosa SL Agarc

Enumeration

Lactobacilli, anaerobic, 37°
for 72 hrs

Supplemented Brucella Agar Agar dilution susceptibility
(s-BA)c, g
testing

C. jejuni, microaerophilic,
42°C for 48 hrs

Supplemented Brucella
Blood Agar (s-BBA)c, g

C. jejuni, microaerophilic,
42°C for 48 hrs

Enrichment

a

Holdeman and Moore, 1975.
McCann, et al., 1996,.
c
Difco Laboratories, Detroit, MI.
d
3M Microbiology Products, St. Paul, MN.
e
Oxoid limited, Hampshire, England.
f
Marshall, 1992.
g
NCCLS, 2001.
b
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mL of salt solution. Resazurin (Sigma-Aldrich) solution was prepared by dissolving 100 mg in
100 mL distilled water. The medium was boiled then cooled, and 5 g/L L-cysteine (SigmaAldrich) was added under a constant flow of CO2. Media was under a flow of CO2 until media
turned from pink to colorless. Media was then transferred to the anaerobic chamber and used for
fecal processing.
Phosphate and magnesium chloride dilution water was prepared as previously described
(Marshall, 1992). Stock phosphate solution was prepared by dissolving 34 g KH2PO4 in 500 mL
distilled water, pH adjusted to 7.2 with 1 N NaOH, the volume brought up to 1 L with distilled
water, and sterilized at 121°C for 15 min. Stock MgCl2 solution was prepared by dissolving 38 g
MgCl2 (Sigma-Aldrich) in 1 L distilled water, and autoclaved at 121°C for 15 min. Stock
solutions were stored at 4°C until use. Class C dilution water was prepared by the addition of
1.25 mL stock phosphate solution and 5 mL MgCl2 solution, and the volume brought up to 1 L
with distilled water. The pH was adjusted to 7.4 (pH 7.2 after autoclaving). Media was
dispensed in aliquots of 10.2 mL into tubes or 105 mL into bottles (to achieve 9.9 and 99 mL
blanks after autoclaving, respectively). Dilution blanks were then autoclaved for 15 min for
tubes, or 30 min for bottles at 121°C. Brucella stearothermophilus, BT Sure biological indicator
for steam sterilization (Barnstead/Thermolyne, Inc., Dubuque, IA), was used as an indicator of
sterility. Spores were autoclaved with the media then incubated at 55°C for 24 hr. Lack of
growth indicated the autoclave was working properly.
For the enumeration of Bifidobacter species, BS-LV agar was prepared as previously
described (McCann et al., 1996). To each liter of Liver Veal agar (Difco), 5 g propionic acid
sodium salt (Eastman Kodak Company, Rochester, NY), 10 g α-lactose (Sigma-Aldrich), 500
mg lithium chloride (Sigma-Aldrich), 400 mg L-cysteine, and 20 mg sodium lauryl sulfate
(Sigma-Aldrich) were added before autoclaving at 121°C for 15 min. Media was tempered to
48°C and 0.1 to 1 mL of sample (in duplicate) was pour plated with approximately 10 mL of BSLV. After solidifying, an additional 10 mL of agar was overlaid and allowed to solidify.
Finally, an additional 10 mL of BS-LV plus neomycin sulfate solution was overlaid and allowed
to solidify before incubation. Neomycin sulfate (Sigma-Aldrich) was prepared by dissolving 100
mg in 6.7 mL sterile distilled water and frozen in 0.5 mL amounts. Just prior to use, 9.5 mL
sterile distilled water was added and mixed. For every 175 mL of BS-LV agar 1 mL of
neomycin solution was added.
62

Campylobacter Agar Base (Karmali; Oxoid, Hampshire, England) was supplemented
with freeze-dried Campylobacter Selective Supplement SR167E (Karmali; Oxoid). One vial of
supplement contained 50 mg sodium pyruvate, 16 mg cefoperazone, 10 mg vancomycin, and 50
mg cyclohexamide. Vial components were dissolved by 2 mL of 50% ethanol and aseptically
added to every 500 mL of sterile Campylobacter Agar Base. Karmali agar was used for the
enumeration of Campylobacter coli and C. jejuni at 42°C. Samples (0.1 mL) were plated in
duplicate using the spread plate method.
Oleandomycin Polymyxin Sulphadiazine Perfringens Agar (OPSP) was used for the
enumeration of Clostridium perfringens. Perfringens Agar Base (OPSP; Oxoid) was mixed and
autoclaved at 121°C for 15 min. Sterile agar was supplemented with freeze-dried Perfringens
Selective Supplements A and B (OPSP; Oxoid). One vial of Supplement A (SR076E) contained
50 mg of sodium sulphadiazine and was dissolved in 2 mL of sterile distilled water. One vial of
Supplement B (SR077E) contained 0.25 mg oleandomycin phosphate and 5000 I. U. polymyxin
B sulphate, and was dissolved in 2 mL sterile distilled water. One vial of Supplement A plus one
vial of Supplement B were added to each 500 mL of sterile Perfringens Agar Base. Medium was
tempered to 48°C and 0.1 to 1 mL of sample (in duplicate) was pour plated with approximately
15 mL of medium.
Rogosa SL Agar (Difco) was used for the enumeration of Lactobacillus. Agar was
mixed, steamed for 30 min, and supplemented with 1.32 mL/L 12 N glacial acetic acid (SigmaAldrich) and adjusted to a final pH of 5.4. Medium was tempered to 48°C and 0.1 to 1 mL of
sample (in duplicate) was pour plated with approximately 15 mL of medium.
RCM was used for the enumeration of anaerobic bacteria to acquire a Total Anaerobe
Count. Medium was tempered to 48°C and 0.1 to 1 mL of sample (in duplicate) was pour plated
with approximately 15 mL of medium.
E.coli/Coliform Petrifilm (3M Microbiology Products, St. Paul, MN) was used for the
enumeration of E. coli and Total Coliform counts. Samples (1 mL) were plated in duplicate.
Blue colonies with gas were read as positive for E. coli. Red colonies with gas were counted as
other coliforms. Blue colonies with gas plus red colonies with gas were considered to be a Total
Coliform count.
Fecal samples. Swine feces were obtained from four Landrace X Yorkshire crossbred
barrows. They were 5 months of age, weighed between 80 and 90 kg, and were housed at the
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University of Kentucky Animal Laboratory. The diet consisted of 85% corn, 12% dehulled
soybean meal, 1% dicalcium phosphate, and less than 1% of limestone, slat, vitamin and mineral
mix. They were receiving no antibiotics. Pigs were kept in individual 5’ x 10’ pens with slatted
floors, continuous lighting, and a constant temperature of approximately 25°C. Water was
available ad libitum. Fresh stool samples were obtained, placed in four separate plastic bags, and
were delivered into the anaerobic chamber within 10 min of collection for processing.
Anaerobic chamber was under a CO2 environment in the absence of O2.
Equal weights of feces from each pig were pooled and blended with anaerobic dilution
solution in a Waring blender for 60 seconds to achieve a 10% (w/v) fecal slurry. Aliquots of 50
mL fecal slurry were transferred into 125-mL serum bottles under a constant flow of CO2.
In vitro treatments and inoculum. Treatments were in a 4 x 2 factorial arrangement and
included type of compound (factor A) and C. perfringens inoculum strain (Factor B). Treatment
combinations are presented in Table 10. Each treatment had 3 replicates.
Carbadox (Sigma-Aldrich) was prepared under a sterile laminar flow hood (UV light for
15 min). A volume of 40 mL of 95% ethanol (0.2 µm filtered) was mixed with 0.12 g carbadox.
The tubes were mixed and stored in 40 mL Fisherbrand (Fisher) plastic tubes surrounded by
aluminum foil at 4°C.
CFA and CGA stock solutions contained 26 mg/mL and were solubilized in 70% ethanol.
Stock solution (1 mL) was added to the appropriate serum bottle containing 50 mL fecal slurry
and 1 mL of inoculum.
Serum bottles were prepared under a constant flow of CO2 using gas jets. Each bottle
was adjusted to contain 1.346% ethanol and was sealed by a butyl rubber stopper then crimpsealed.
Clostridium cultures were transferred twice in Cooked Meat Medium and incubated
anaerobically for 24 hr at 37°C. The cultures were then streaked onto RCM with 1.5% agar and
incubated anaerobically for 24 hr at 37°C. Cultures were suspended in sterile dilution water to
achieve 0.5 McFarland Standard, and 1 mL of the appropriate culture was anaerobically
transferred into sealed serum bottles using sterile 1-mL syringes. After the addition of the
compounds and inoculum, serum bottles were incubated in a shaking water bath at 125 rpm for
24 hr at 39°C.
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Table 10. List of in vitro treatments and inoculum used in this study.
Treatment

Inoculuma

Compound

A
B
C
D
E
F
G
H
I

None
92Db
92Gc
92D
92G
92D
92G
92D
92G

None
None
None
CFAd
CFA
CGAe
CGA
Carbadoxf
Carbadox

a

Inoculum level approximately 2 x 106 bacteria per mL
Culture 92D = Clostridium. perfringens University of Kentucky isolate from poultry.
c
Culture 92G= C. perfringens ATCC 13124.
d
CFA = 500 ppm caffeic acid.
e
CGA = 500 ppm chlorogenic acid.
f
Carbadox = 15 ppm Carbadox.
b
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Chemical analysis. Samples were taken at 0, 0.75, 1.5, 2.5, 4, 6, 12, and 24 hr. A
volume of 1 mL was removed anaerobically from each serum bottle with a syringe and
centrifuged for 5 min at 20,800 x g (Eppendorff Centrifuge 5417C, Brinkman Instruments, Inc.,
Westbury, NY). The supernatant was drawn off, placed in storage vials, and stored at a
temperature of -20°C until further analysis.
Lactate was analyzed by an enzymatic method using lactate dehydrogenase (Hohorst,
1965). For every 50 assays, the lactate premix contained 1.42 g hydrazine sulfate (Nutritional
Biochemicals Corporation, Cleveland, OH), 2.1 g glycine (Sigma-Aldrich), 0.056 g Na2EDTA•2H2O (Fisher) dissolved in 14 mL distilled water, and 20 mL 2 N NaOH. The pH of the
premix was adjusted to 9.5 using 1 N NaOH, and 84 mg β-Nicotinamide Adenine Dinucleotide
(β-NAD; Sigma-Aldrich) and 200 U lactate dehydrogenase (Sigma-Aldrich) were added.
Samples were thawed and 50 µL dispensed into glass tubes (in duplicate). A standard curve was
prepared using 4.44 mM lactate standard (Sigma-Aldrich). Premix (1 mL) was added, tubes
were gently mixed and incubated 45 min at room temperature. Absorbance was read at 340 nm.
The maximum absorbances (λmax) at pH 9.5 are 329 nm for CFA and 346 nm for CGA
(Friedman and Jürgens, 2000). The λmax of the compounds at pH 9.5 allows for interference with
the lactate assay read at 340 nm. A standard curve was prepared using 500 ppm CFA and CGA
stock solutions.
To confirm the presence or absence of lactate, high pressure liquid chromatography
(HPLC) was used. A Sulpelcogel™ H HPLC Column (25 cm x 4.6 mm; Sulpelco, Bellefonte,
PA) was run at 30°C using 0.1% phosphoric acid as the eluent at a rate of 0.17 mL/min on a
Ranin HPXL solvent delivery system (Ranin Instrument Co., Inc., Woodburn, MA). A lactate
standard (50 µL of 4.44 mM) was eluted to serve as a control.
Volatile fatty acids were analyzed by gas chromatography (Supelco, Inc., 1985; Gow
Mac chromatograph model 580 equipped with a Supelco 1000 column [1% H3PO4, 100/120
mesh]). Samples were thawed, 400 µL dispensed into centrifuge tubes, and 125 µL of 25%
meta-phosphoric acid (Fisher) was added. Samples were centrifuged for 7 min at 20,800 x g,
and 500 µL of clarified sample was dispensed into Wheaton GC vials before analysis.
Initial slurry pH and final pH (time 0 and 24 hr) readings were recorded using Accumet
pH Meter 930 (Fisher).
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Differentiation of C. jejuni. In order to differentiate between C. coli and C. jejuni, the
hippurate reaction was observed. Individual colonies were picked from Karmali agar. The
colonies (18 total, 10 and 8 from each plate) were from the 10-5 dilution of the initial fecal slurry.
They were each suspended in 5 mL of BB, streaked onto s-BBA, and incubated for 48 hr at 42°C
in a microaerophilic incubator. The resulting colonies were then tested for the hippurate reaction
(in duplicate) according to methods previously described (BAM, 1998). Approximately 2 mm
loopfull of the culture was suspended in 0.4 mL of a 1% sodium hippurate solution and
incubated for 2 hr in a 37°C water bath. Sodium hippurate (Sigma-Aldrich) solution was
prepared by dissolving 0.1 g in 10 mL distilled water and filter sterilized (0.2 µm pore size,
Millipore). After incubation, 0.2 mL of 3.5% ninhydrin reagent (1, 2, 3-triketohydrindene) was
added, agitated, and incubated for an additional 20 min. Ninhydrin reagent (R47; Eastman
Kodak) was prepared by dissolving 3.5 g in 100 mL of a 1:1 mixture of acetone (Fisher) and 1butanol (Fisher). Campylobacter jejuni ATCC 33291 was used as the quality control organism.
A color change to deep violet was considered a positive reaction.
Statistical analyses. Data were analyzed as a 4 x 2 factorial in a completely randomized
design using PROC GLM of SAS (1988). Treatment combinations defined grouped, structured
populations, and the Bonferroni t-test for nonorthogonal contrasts was used to determine
differences between treatments. One serum bottle was the experimental unit, with 3 replicates
per treatment. Bacterial counts were converted to logarithm units (log10) before statistical
analysis. Bacterial counts were analyzed at 24 hr, while VFA concentrations were analyzed at
each time point. Correlations between bacterial counts at 24 hr were analyzed using the PROC
CORR procedure of SAS. Correlations between bacterial counts at 24 hr and VFA
concentrations at 24 hr were analyzed using the PROC CORR procedure using the Pearson and
Spearman options.
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CHAPTER 5
Results and Discussion
Methods development
Some preliminary work was required to develop the methods to be used for the main
studies. The National Committee for Clinical Laboratory Standards methods for macrobroth
dilution technique (NCCLS, 2000), agar dilution technique (NCCLS, 2001), and the in vitro
incubation were of concern. The results are discussed in more detail in Chapter 3, and will only
be briefly summarized in the following paragraphs.
Two bacterial cultures were eliminated in Study 1. Salmonella enteritidis 108A and
Escherichia coli ATCC 25404 were not able to survive in broth containing 3% ethanol. The
alcohol interfered with the macrobroth dilution technique when trying to determine the MICs of
alcohol soluble antimicrobials.
Study 2 determined that blood should not be used in agar dilution plates for determining
MICs. Components in the blood interacted with CFA and CGA, preventing the compounds from
inhibiting bacterial growth. This is a problem when attempting to determine MICs, giving false
results. Staphylococcus aureus grew well on MHA with 7% ethanol. Clostridium perfringens
grew well on all agars containing 7% ethanol except for RCM. This suggested that type of
media influenced growth when agar contained ethanol.
Study 3 resolved the best combination of media to use for growth of cultures and for agar
dilution plates used for testing MICs. Ethanol concentration is a concern when using an agar
dilution method (compared to broth). Growth of C. perfringens was supported when RCM was
used as the source agar then transferred to BA containing 3.5% ethanol. This determined type of
media to be used for the MICs of the compounds on C. perfringens cultures. Campylobacter
jejuni growth was inhibited on all agars containing 3.5 and 7% ethanol, and required further
investigation.
Study 4 demonstrated that C. jejuni growth was supported on agar containing less than or
equal to 1.5% ethanol. C. jejuni grew well on source agar s-BBA with no ethanol, and BA with
1.5% ethanol. For MIC testing, s-BBA was chosen as the source agar. Since hemin and vitamin
K1 do not interfere with determining the MICs, s-BA was chosen for agar dilution testing.
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However, another limiting factor emerged when CFA would not solubilize. Despite the visibly
insoluble compound, CFA inhibited C. jejuni at 480 ppm.
Study 5 further defined specific media formulations to be used in MIC testing of C.
jejuni. It was determined that 0.5 mL of CFA and CGA stock solutions solubilized in 60%
ethanol were to be used in agar dilution medium.
One final problem arose during a preliminary in vitro incubation. Campylobacter did not
survive the incubation period when swine feces were introduced. This complication could not be
addressed satisfactorily, indicating that this particular in vitro method was not adequate to study
Campylobacter dynamics within the microbial ecology of swine feces.
Minimum inhibitory concentrations
A summary of results can be found in Table 11. While several studies exist on the
antimicrobial nature of CFA, there are few that examine CGA. All Gram-positive organisms
were affected by CFA, and all but one was affected by CGA. Three of the four S. aureus
cultures were inhibited by 100 ppm CFA and 500 ppm CGA. The remaining S. aureus ATCC
43300 is a methicillin- and oxacillin-resistant strain that required 200 ppm CFA and 500 ppm
CGA for inhibition. Both C. perfringens cultures were inhibited by 300 ppm CFA. However,
the toxin producing strain C. perfringens ATCC 13124 was not susceptible to 1000 ppm CGA.
Yet, the other C. perfringens strain isolated from poultry was inhibited by 400 ppm CGA. These
results agree with other studies where S. aureus and C. perfringens were inhibited by CFA
(Debrauwer et al., 1989; Tunçel and Nergiz, 1993; Binutu et al., 1996; Lee et al., 2001).
In this study, Gram-negative organisms (E. coli, Salmonella, and Campylobacter) were
not susceptible to 1000 ppm CFA or CGA. Two other studies concurred with these findings. E.
coli and Pseudomonas aeruginosa were not inhibited by 500 ppm CFA (Debrauwer et al., 1989).
CFA was solubilized in DMSO, and a microplate method with nutrient broth was used. In
another study, E. coli was not inhibited by CFA using methanol as a solvent (Lee et al., 2001). A
disk diffusion assay on Eggerth-Gagnon (EG) agar was the method used.
Other studies that reported inhibition of Gram-negative organisms used different
solvents, media, or MIC methods. When inhibition was successful, common methods between
the studies included using water as the solvent (Aziz et al., 1998; Tsou et al., 2000), use of
trypticase soy broth or agar (Herald and Davidson, 1983; Tunçel and Nergiz, 1993; Tsou et al.,
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Table 11. Minimum inhibitory concentrations (µg/mL) of caffeic acid and chlorogenic
acid.
Caffeic
acid

Chlorogenic
acid

Escherichia coli
ATCC 11775

NI

NI

Escherichia coli
ATCC 25922

NI

NI

Escherichia coli
ATCC 43895

NI

NI

Salmonella typhimurium
ATCC 13311

NI

NI

Salmonella typhimurium
ATCC 700408

NI

NI

Salmonella spp.
TT42

NI

NI

Campylobacter jejuni
ATCC 33291

NI

NI

Staphylococcus aureus
ATCC 12600

100

500

Staphylococcus aureus
ATCC 25923

100

500

Staphylococcus aureus
ATCC 27543

100

500

Staphylococcus aureus
ATCC 43300

200

500

Clostridium perfringens
ATCC 13124

300

NI

Clostridium perfringens
92D

300

400

Culture

a

NI = No inhibition
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2000), and a broth dilution method (Herald and Davidson, 1983; Tsou et al., 2000). Tsou et al.
(2000) were also able to inhibit Shigella with CGA.
The pH of the media can also have an affect. Herald and Davidson (1983) found that S.
aureus was 46% more inhibited by 1000 ppm CFA in broth at pH 7 compared to pH 6. In the
same study, E. coli was 16% more inhibited at pH 6 compared to pH 7. The media used in this
study for MIC testing were MHB (pH 7.3) and BA (pH 7), and could be a factor contributing to
the susceptibility of Gram-positive bacteria and the resistance of the Gram-negative bacteria to
the compounds. The pH determines the chemical nature of the compound, affecting polarity and
solubility, along with ability to inhibit some microorganisms (Baranowski and Nagel, 1982).
One interesting observation occurred when C. jejuni initially appeared to be susceptible
to 480 ppm CFA. This transpired during the methods development (Study 4, Chapter 3). Later,
C. jejuni was completely insensitive to 1000 ppm CFA. The major difference was the percent
ethanol used as a solvent. Initially, 28% ethanol was used, while 60% ethanol was used later
(1.4 and 1.5% ethanol in agar, respectively). This suggests that water solubility played a role in
inhibition for this particular microorganism. This agrees with the studies that used water as a
solvent and were able to inhibit Gram-negative organisms (Aziz et al., 1998; Tsou et al., 2000).
However, Tunçel and Nergiz (1993) solubilized CFA in 95% ethanol and were able to inhibit
Gram-positive and Gram-negative bacteria, but used an agar dilution method with trypticase soy
agar. As supported by the findings of Stern et al. (1988), type of media my play a critical role in
determining susceptibility to antimicrobials.
In vitro incubation
Results from the MIC testing revealed that concentrations of 500 ppm of CFA and CGA
were sufficient to inhibit most Gram-positive organisms. This level was then chosen for the
CFA and CGA treatments in the in vitro incubation.
Upon statistical analysis, data were consistent with the absence of interactions between
type of compound (factor A) and C. perfringens inoculum strain (factor B). Therefore, data were
pooled according to type of compound and analyzed as a one-way classification of treatments.
Treatment A was the control and contained no compound (A, B, and C pooled), treatment B
contained 500 ppm CFA (D and E pooled), treatment C contained 500 ppm CGA (F and G
pooled), and treatment D contained 15 ppm carbadox (H and I pooled).
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Carbadox is used as a growth promoter in swine, and its use has been banned by the
European Union (EC, 1998b). Many studies have been done on the ability of carbadox to
improve growth performance and the prevention or treatment of swine dysentery (Yen and Pond,
1993; Raynaud et al., 1981). Carbadox is thought to promote growth by reducing the mass of the
small intestines, thereby decreasing maintenance energy (Yen et al., 1987). Few studies are
available on the effect of carbadox on the microbial ecology of the gut. White et al. (2002)
studied microbial populations in the pig in vivo, but found no differences between the basal diet
and carbadox supplementation on Bifidobacteria, lactobacilli, E. coli, coliforms, total
aerotolerant anaerobes, Salmonella, or C. perfringens counts in feces.
Effect of treatment on bacterial counts. Counts from all populations except
Bifidobacteria were reduced by approximately 1 log after 24 hr of incubation. This can be
explained by the lack of substrate in the medium used for the fecal slurry and accumulation of
VFAs that inhibit some bacteria. The analysis of variance for bacterial counts are presented in
Figures 9-15.
Treatment containing CGA, CFA, and carbadox had lower total aerotolerant anaerobe
counts than the control (9.3, 9.4, and 9.7 versus 10.3 log, p<0.0001; Figure 9). CFA, CGA, and
Carbadox were not different from each other (p>0.12). Although there were statistical
differences, a reduction of 1 log is required to be considered to microbiologically important.
There was a 0.6 log reduction for Carbadox, 0.9 log reduction for CGA, and a 1 log reduction in
the CFA treatment. There was a very high, positive correlation (r >0.8, p<0.05) between total
anaerobe and Bifidobacteria counts in the control (r=0.87605), CFA treatment (r=0.90116), and
carbadox treatment (r=0.99514). In other words, 77, 81, and 99% of the variation in total
anaerobe counts can be explained by the variation in Bifidobacteria counts in the control, CFA,
and carbadox treatments, respectively. However, this does not establish a cause and effect
between the two counts.
Treatments containing CGA, CFA, and carbadox had lower Bifidobacteria counts than
the control (9.2, 9.4, and 9.7 versus 10.3 log, p<.0001; Figure 10). However, the three treatments
were not different from one another (p>0.08). The differences between the control and the
treatments were 0.6 log reduction for carbadox, 0.9 log reduction for CFA, and 1.1 log reduction
for CGA. This contradicts the findings of Lee et al. (2001) where Bifidobacteria were not
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9.6
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9.0
8.8
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CFA

CGA

Cbx

Figure 9. Total Aerotolerant Anaerobe counts (log10 CFU/g) from the in vitro incubation at
24 hours. Bars represent + standard error (SE) of the mean. Treatments with the unlike letters
were different (p<0.0001). Treatments included control with no compound (Control), 500 ppm
caffeic acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Figure 10. Bifidobacteria counts (log10 CFU/g) from the in vitro incubation at 24 hours.
Bars represent + standard error (SE) of the mean. Treatments with the unlike letters were
different (p<0.0001). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Figure 11. Lactobacilli counts (log10 CFU/g) from the in vitro incubation at 24 hours. Bars
represent + standard error (SE) of the mean. Treatments with unlike letters were different
(p<0.01). Treatments included control with no compound (Control), 500 ppm caffeic acid
(CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Figure 12. Total Coliform counts (log10 CFU/g) from the in vitro incubation at 24 hours.
Bars represent + standard error (SE) of the mean. Treatments with the unlike letters were
different (p<0.0001). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Figure 13. Escherichia coli counts (log10 CFU/g) from the in vitro incubation at 24 hours.
Bars represent + standard error (SE) of the mean. Treatments with the unlike letters were
different (p<0.001). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Figure 14. Percentage of Escherichia coli present in Total Coliform counts from the in vitro
incubation at 24 hours. Bars represent + standard error (SE) of the mean. Treatments with the
same letter are not different (p=0.16). Treatments included control with no compound (Control),
500 ppm caffeic acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Figure 15. Clostridium perfringens counts (log10 CFU/g) from the in vitro incubation at 24
hours. Bars represent + standard error (SE) of the mean. Treatments with like letters were not
different (p>0.05). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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inhibited by CFA. Perhaps CFA and CGA metabolites created by other bacteria were toxic to
the Bifidobacteria in this study.
For lactobacilli counts, there was one replicate from the control where no colonies grew.
No growth was observed on the 10-7 dilution, and lower dilutions were not plated. Therefore,
that replicate was excluded from analysis. The treatment containing CGA had lower lactobacilli
counts than the control (8.2 versus 9.1 log, p<0.01; Figure 11). However, there were no
differences between CGA, CFA, and the carbadox treatments (8.2, 8.6, and 8.7, p>0.18). Again,
Lee et al. (2001) found that Lactobacillus acidophilus was not susceptible to CFA, suggesting
that some lactobacilli may be susceptible to CFA and CGA metabolites produced by other
bacteria.
Lactobacilli and Bifidobacteria are associated with beneficial effects on intestinal health.
They interfere with adherence of pathogens to intestinal cells, elicit an immune response of the
host, produce chemicals that inhibit the growth of pathogens, and restore the ecological balance
of normal intestinal flora (Sullivan and Nord, 2002). Reduced counts of these bacteria have been
related to sick animals (Robinson et al., 1984).
The treatment containing carbadox had lower total coliform counts than CFA, CGA, and
the control (5.2 versus 5.6, 5.8, and 5.9 log, p<0.0001; Figure 12). However, there was only a
0.7 log reduction. White et al. (2002) were able to lower coliforms counts with carbadox in the
jejunum and cecum of the pig by 0.9 and 1.3 logs, but did not have the same results when
analyzing fecal swab samples. Coliforms are non-spore-forming, Gram-negative, rod-shaped
bacteria that ferment lactose and produce gas and acid. They are often used as an indicator of the
potential presence of pathogens (Rompré et al., 2002).
The treatments containing carbadox and CFA had lower Escherichia coli counts than
CGA and the control (4.7 and 4.9 versus 5.2 and 5.3 log, p<0.001; Figure 13). The CFA and
carbadox treatments were not different from each other (p>0.35). The CGA treatment and the
control were not different from each other as well. In this study E. coli were not inhibited by the
compounds during MIC testing, and responded differently to the in vitro incubation. This could
be due to type of media used for MIC testing (previously discussed). There was a very high,
positive correlation between E. coli and total coliform counts in the control (r=0.89071) and
carbadox treatments (r=0.88492). Escherichia coli are thermotolerant bacteria and are a part of
the natural flora of the intestine, and is known as a fecal coliform (Rompré et al., 2002). Many
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different strains are associated with foodborne illnesses (Levine, 1987) and diarrheal diseases in
swine (Shu et al., 2001).
The treatment containing CFA had lower percentages of E. coli in total coliform counts
than CGA, the control, and carbadox (18.9 versus 25.1, 26.3, and 31.2%, p<0.01; Figure 14).
The control, CGA, and carbadox treatments were not different from each other (p>0.09).
Percentage of E. coli was used to study the dynamics of a section of the coliform population. A
reduced percentage means that the proportion of other coliforms increased. The significance of
this observation is beyond the scope of this study.
There were no differences in Clostridium perfringens counts between the control, CFA,
CGA, and carbadox treatments (2.7, 2.6, 2.5, and 2.4 log, p=0.37; Figure 15). Despite the ability
of CFA and CGA to inhibit growth of C. perfringens during the MIC testing in this study and by
Debrauwer et al. (1989), in vitro there appeared to be no susceptibility to the compounds. This
suggests that C. perfringens is not susceptible to the metabolic end products of CGA and CFA.
C. perfringens produces toxins and causes foodborne illness in humans (Shandera et al, 1983) as
well as depressing swine growth performance in livestock (McDonel, 1980; Strauch, 1987c).
Three colonies survived the in vitro incubation on Karmali Agar, selective for C. jejuni
and C. coli at 42°C. After a Gram stain procedure, the surviving colonies were determined to be
Gram-positive cocci. Since Campylobacter are Gram-negative rods, the surviving colonies were
ruled out, concluding that Campylobacter did not survive the in vitro incubation. Because of the
bacterium’s fastidious nature, few studies have been done to determine the average number of
Campylobacter found in feces. Weijtens et al. (1999) found a variation in counts between pigs,
ranging from less than 630 CFU/g feces up to 3.6 x 106 CFU/g. In this study, it was determined
that there were nearly 8 x 105 CFU/g in swine feces (fresh wet weight), but were not able to
survive the in vitro incubation.
The hippurate reaction was used to differentiate C. coli from C. jejuni in the initial fecal
slurry. The control strain produced a clear, deep violet reaction, testing positive as C. jejuni.
Ten and 8 colonies were isolated from two 10-5 dilution plates. All eighteen colonies tested
negative. Nielsen et al. (1997) found that 95% of thermophilic campylobacter in swine feces
were identified as C. coli, where C. jejuni only accounted for 4%. Relative to this study, an
estimated 3.2 x 104 CFU/g were C. jejuni.
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Effect of treatment on volatile fatty acids. Volatile fatty acids (VFAs) are end products
of microbial metabolism, and may provide an indication of microbial activity in the intestinal
tract. They also serve as an energy source to the host animal. The analysis of variance for VFAs
is presented in Figures 16-23.
Acetate concentrations remained lower for the carbadox treatment throughout the
incubation (Figure 16). At 24 hr, the treatment containing CGA had higher acetate levels than
the control and CFA treatment (40.3 versus 38.6 and 38.6 mM, p<0.0001), and the carbadox
treatment had lower acetate levels than the control, CFA, and CGA treatments (31 versus 38.6,
38.6, and 40.3 mM, p<0.0001). There was no difference between the control and the CFA
treatment (p=1.0)). One explanation for higher amounts in the CGA treatment could be that
CGA was used as an electron sink for acetogenesis (Sunvold et al., 1995; Weimer, 1998).
Excess H2 can be deposited onto CGA metabolites (Imkamp and Müller, 2002). The reduction
in available H2 can cause a shift in fermentation, decreasing the carbon flow into succinate,
ethanol, and lactate while increasing the flow to acetate (Wolin, 1975). Acetate can then
transported for use by muscle as an energy substrate (Jensen, 2001).
At the end of the incubation, the treatment containing carbadox had lower propionate
levels than the CFA and CGA treatments (8.9 versus 9.5 and 9.5 mM, p<0.01; Figure 17).
However, the carbadox treatment was only 0.6 mM lower, and was not different from the control
at 9.3 mM (p>0.07). Plus, there were no differences between the three treatments at any other
time point. After absorption, propionate is transported to the liver and converted to glucose and
used for energy. Increased amounts of propionate are associated with increased production of
animal protein (Wolin, 1981).
At 24 hr, the treatment containing carbadox had lower acetate:propionate ratios than the
control, CFA, and CGA treatments (3.5 versus 4.1, 4.1, and 4.2 units, p<0.0001; Figure 18).
This was due to the reduced acetate levels in the carbadox treatment. CFA was not different
from the control (p=0.73). However, the CGA had higher acetate:propionate ratios than the
control and CFA treatment (p<0.0001). This was due to the increased acetate levels in the CGA
treatment. Acetate to propionate ratio has been used as a measure of reduction of Gram-positive
cocci that produce acetate in ruminants (Weimer, 1998). The change in ratio involves both
reduction of acetate and increased propionate production. This was not observed in this study.
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Figure 16. Acetate concentration (mM) trends over time during the in vitro incubation.
Mean + standard error (SE). ◊ Control; 500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid; {
15 ppm carbadox; * p<0.05.
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Figure 17. Propionate concentration (mM) trends over time during the in vitro incubation.
Mean + standard error (SE). ◊ Control; 500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid; {
15 ppm carbadox; * p<0.05.
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Figure 18. Acetate to propionate ratio trends over time during the in vitro incubation.
Mean + standard error (SE). ◊ Control; 500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid; {
15 ppm carbadox; * p<0.05.
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Figure 19. Butyrate concentration (mM) trends over time during the in vitro incubation.
Mean + standard error (SE). ◊ Control; 500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid; {
15 ppm carbadox; * p<0.05.
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Figure 20. Valerate concentration (mM) trends over time during the in vitro incubation.
Mean + standard error (SE). ◊ Control; 500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid; {
15 ppm carbadox; * p<0.05.
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Figure 21. Isobutyrate concentration (mM) trends over time during the in vitro incubation.
Mean + standard error (SE). ◊ Control; 500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid; {
15 ppm carbadox; * p<.05.
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Figure 22. Isovalerate concentration (mM) trends over time during the in vitro incubation.
Mean + standard error (SE). ◊ Control; 500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid; {
15 ppm carbadox; * p<0.05.
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Figure 23. Total volatile fatty acid concentration (mM) trends over time during the in vitro
incubation. Mean + standard error (SE). ◊ Control; 500 ppm caffeic acid; ∆ 500 ppm
chlorogenic acid; { 15 ppm carbadox; * p<0.05.
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Gram-negative as well as Gram-positive bacteria were reduced, and propionate production was
not increased.
Butyrate concentrations remained lower for the carbadox treatment beginning at 2.5 hr
(Figure 19). At the end of the incubation, the carbadox treatment had lower butyrate levels than
the control, CGA, and CFA treatments (7.7 versus 11.2, 11.3, and 11.5, p<0.0001). The control,
CFA, and CGA treatments were not different (p>0.18). The lower butyrate production resembles
reduction of Gram-positive organisms in the rumen (Wolin, 1981). In this study, selected Grampositive organisms were reduced, namely Bifidobacteria and lactobacilli. Other bacteria may be
stimulated to produce butyrate in the presence of excess acetate (Russell, 2002). However, the
transformation of excess acetate into butyrate in mixed cultures could also account for the
increase in concentrations (Russell, 2002). Butyrate is the preferred energy source of energy for
colonic epithelial cells (Sunvold et al., 1995). Reduced butyrate production by the carbadox
treatment could help to explain the reduction of intestinal mass of swine.
At the end of the incubation, the carbadox treatment had lower valerate levels than the
control, CGA, and CFA treatments (1.2 versus 1.5, 1.5, and 1.6 mM, p<0.0001; Figure 20). The
control, CFA, and CGA treatments were not different (p>0.14).
There were no differences in isobutyrate levels between the control, CFA, CGA, and
carbadox treatments (1.2, 1.3, 1.5, and 1.5 mM, p=0.2689; Figure 21).
The treatment containing carbadox had lower isovalerate levels than CGA and CFA
treatments (1.4 versus 1.5 and 1.5 mM, p<0.01; Figure 22), and there was no difference between
the control and carbadox treatment (1.5 and 1.4 mM, p>0.58). The control was also not different
from the CGA and CFA treatments (p>0.09). Still, isovalerate levels in the carbadox treatment
were merely 0.1 to 0.2 mM lower, and may not be biologically important.
Valerate, isobutyrate, and isovalerate are branched-chain fatty acids that are formed as a
result of protein fermentation in the distal colon (Blaut, 2002). Increased levels of these three
compounds may indicate an increase in protein metabolism (Sakata et al., 1999). Overall,
valerate, isobutyrate and isovalerate concentrations increased through out the incubation, and
was most likely due to microbial protein released from lysed cells.
The treatment containing carbadox had lower total VFA concentrations than the control,
CFA, and CGA treatments (51.8 versus 63.2, 64.1, and 65.4 mM, p<0.0001; Figure 23). This
was mostly due to the lower acetate and butyrate concentrations in the carbadox treatment.
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There were no differences between the control, CFA, and CGA treatments (p>0.06). Total VFAs
are a measure of overall microbial activity in the gut. In addition to the ability of CFA, CGA,
and CGA to effect microbial populations, they were able to effect the chemical aspect of the
microbial ecology of swine feces.
pH analysis. The pH at 0 and 24 hr are presented in Figure 24. The pH was 6.5 for the
initial fecal slurry at 0 hr. At the end of the incubation, the pH of the control dropped by 0.1,
while the CFA, CGA, and carbadox treatments were lowered by 0.2 units.
Lactate analysis. The control and the carbadox treatment showed a steady amount of
lactate (0.3-0.6 mM) over the entire incubation (0 to 24 hr) as determined by the lactate assay.
However, the CFA and CGA interfered with the assay, exhibiting higher amounts from 0.75 to12
hr. To determine the amount of lactate present without interference, HPLC was performed.
Results demonstrated that lactate levels in the CFA and CGA treatments were consistently less
than 1 mM for all time points (data not shown). It can then be assumed that lactate
measurements obtained from CFA and CGA treatments were due to CFA and CGA.
The concentrations of CFA and CGA declined over time, and by 12 hr of incubation
levels had diminished to below 1 mM for both compounds (Figure 25). Reduction of the
compounds over time was caused by microbial metabolism. This is supported by several studies.
Two strains of Streptococcus gallolyticus were able to decarboxylate caffeic acid (removal of
COOH group) to produce the metabolite 4-vinylcatechol (Chamkha et al., 2002). The phenolic
acid decarboxylase (PAD) enzyme has been found in Lactobacillus plantarum, Pediococcus
pentosaceus, Bacillus subtilis, and Bacillus pumilus (Barthelmebs et al., 2001), and was able to
decarboxylate CFA. The authors also suggest that PAD activity may be a stress response to
avoid the toxicity of the compounds, though some species showed more enzyme activity than
others did. The strictly anaerobic bacterium Acetobacterium woodii was able to reduce a double
bond in CFA (caffeate) to produce hydrocaffeate (3,4-hydroxyphenyl propionic acid) (Imkamp
and Müller, 2002). By using CFA as an electron acceptor, A. woodii was able to generate ATP.
Besides decarboxylation and reduction, intestinal microflora can also dehydroxylate CFA
(removal of OH group(s); Scheline, 1968; Chesson et al., 1999). Other metabolic products of
CFA from hind-gut fermentation include 4-ethylcatechol, 3-hydroxyphenylpropionic acid
(3HPP), and 3-phenylpropionic acid (3PPA; Scheline, 1968; Chesson et al., 1999).
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The metabolic products of CFA can be further used by other intestinal microbes (crossfeeding). Phenylpropionic acid (PPA) increased the adherence of Ruminococcus albus to
cellulose (Pegden et al., 1998), which encourages the breakdown of plant material in the gut.
There are several pathways in which E. coli can metabolize 3-hydroxycinnamic acid (3HCI),
PPA, and 3HPP (Díaz et al., 2001). Metabolism involves breaking the aromatic (benzene) ring
resulting in the production of succinic acid, acetyl-CoA, pyruvic acid, and fumaric acid. These
end products can then enter other metabolic pathways including the citric acid cycle to generate
reducing equivalents (NADH) and energy (ATP; Moran et al., 1994b).
Chlorogenic acid can also be metabolized by microbes. Couteau et al. (2001) isolated
Bifidobacterium lactis, two strains of Lactobacillus gasseri, and three strains of E. coli from
human feces. They demonstrated that these bacteria were able to hydrolyze CGA using the
enzyme cinnamoyl esterase, producing CFA and quinnic acid. Once CGA is hydrolyzed, CFA is
available to be further metabolized by other microbes.
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CHAPTER 6
Summary
The objectives of this study were to determine the MICs of CFA and CGA against
selected pathogens and to examine the effects of these compounds on the microbial ecology of
swine feces. However, the standard or established methods proved inconsistent and these
methods had to be modified.
The standard method for testing MICs for aerobic bacteria was not able to support the
growth of two Gram-negative bacteria in the presence of a low level of ethanol, and were
excluded from further testing. The standard method for testing the MIC for anaerobic and
microaerophilic bacteria was used with the following adjustments: blood was not used in agar
dilution plates, RCM was used as a source agar for C. perfringens, 1 mL of a 20x solution in
70% ethanol was used in agar dilution plates for C. perfringens testing, and 0.5 mL of a 40x
solution in 60% ethanol was used in agar dilution plates for C. jejuni testing. For the in vitro
incubation, the method used was unable to support the survival and growth of C. coli and C.
jejuni in the presence of swine feces.
Upon completion of the methods development, the MICs were determined. CFA and
CGA did not inhibit Gram-negative bacteria. CFA inhibited Staphylococcus aureus ATCC
12600, S. aureus ATCC 25923, and S. aureus ATCC 27543 at 100 ppm, S. aureus ATCC 43300
at 200 ppm, and Clostridium perfringens ATCC 13124 and C. perfringens 92D at 300 ppm.
Chlorogenic acid inhibited all four S. aureus strains at 500 ppm, and C. perfringens ATCC
13124 at 400 ppm.
The concentrations of CFA and CGA to be used for the in vitro incubation were based on
the MIC results at 500 ppm. The in vitro incubation examined specific bacterial populations and
volatile fatty acid concentrations. CFA lowered the counts of Bifidobacteria, coliforms,
Escherichia coli, total anaerobes, and percent E. coli (p<0.01). Percentage of E. coli was 12%
lower than in the carbadox treatment. CGA lowered Bifidobacteria, lactobacilli, and total
anaerobe counts (p<0.01). E. coli counts were 0.5 log higher than in the carbadox treatment, and
percent E. coli was 6% higher than in the CFA treatment. CFA did not affect VFA production
(p>0.05). CGA increased acetate concentrations by 1.7 mM (p<0.05). Carbadox lowered the
concentrations of acetate, propionate, butyrate, isovalerate, and total VFAs (p<0.01). VFA
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concentrations (excluding acetate) between caffeic and chlorogenic acid treatments were not
different (p>0.05). Both compounds disappeared by the end of incubation.
CGA is present in many foods, and can travel to the large intestines where it can inhibit
microorganisms or be metabolized into CFA and quinnic acid. CFA can then inhibit microbes or
be metabolized by other gut microorganisms. CFA had similar actions to carbadox in inhibiting
some of the same bacteria. A decreased number of pathogens may prevent disease, and a
reduced bacterial load can lessen competition for nutrients with the animal. At the same time,
VFA production for the CFA treatment did not decrease, mainly due to acetate and butyrate
concentrations. Decreased pathogens and bacterial load without decreased VFA production
could encourage the growth performance of swine.
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APPENDIX
Appendix Table 1. Initial (0 hours) and final (24 hours) bacterial counts (log10 CFU/g†) from the in vitro incubation‡.
Total
Total
Anaerobes
BifidoClostridium Escherichia
Treatment C. jejuni
Lactobacilli
Coliforms
%E. coli
(Aerotolerant)
bacteria
perfringens
coli
(p<0.0001)

Initial

5.9 + 0.04 10.1 + 0.22

(p=0.0064)

10.1 + 0.33

(p=0..3693)

(p=0.0005)

(p=<0.0001)

(p=0.0081)

(p<0.0001)

3.7 + 0.06

6.5 + 0.04

7.1 + 0.73

27.7+ 1.8

11.5 + 0.04

Final
Control

0

10.3 + 0.15 a

9.1 + 0.25 a

2.7 + 0.21 a

5.3 + 0.37 a

5.9 + 0.28 a

26.3 + 6.0 ab

10.3 + 0.20 a

CFA

0

9.4 + 0.14 b

8.6 + 0.07 ab

2.6 + 0.29 a

4.9 + 0.07 bc

5.6 + 0.05 a

18.9 + 2.5 b

9.4 + 0.12 b

CGA

0

9.2 + 0.43 b

8.2 + 0.60 b

2.5 + 0.31 a

5.2 + 0.09 ab

5.8 + 0.10 a

25.1 + 5.8 a

9.3 + 0.04 b

Cbx

0

9.7 + 0.45 b

8.7 + 0.40 ab

2.4 + 0.35 a

4.7 + 0.17 c

5.2 + 0.14 b

31.2 + 0.1 a

9.7 + 0.42 b

†CFU/g = colony forming units per grams of feces (wet weight) + standard deviation (SD).
‡Treatments with unlike letters were different (p<0.05). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Appendix Table 2. Acetate concentrations (mM †) at various time points from the in vitro incubation‡.
Treatment
0 hr
0.75 hr
1.5 hr
2.5 hr
4 hr
6 hr
12 hr
(p=0.056)

(p=0.1425)

(p=0.0056)

(p=0.004)

24 hr

(p<0.0001)

(p=0.0123)

(p<0.0001)

Control

8.4 + 0.9

9.3 + 0.8 a

11.6 + 1.0 a

14.8 + 1.2 a

16.3 + 0.7 ab

19.5 + 0.9 a

26.6 + 1.4 a

38.6 + 0.7 a

CFA

8.4 + 0.9

8.7 + 0.1 a

11.4 + 0.9 a

13.6 + 0.8 ab

15.9 + 0.9 ac

18.5 + 0.5 a

26.3 + 1.2 a

38.6 + 0.7 a

CGA

8.4 + 0.9

10.0 + 1.0 a

12.7 + 0.2 a

14.9 + 0.2 a

17.2 + 0.6 b

19.5 + 1.2 a

27.1 + 3.5 a

40.3 + 1.0 b

Cbx

8.4 + 0.9

9.0 + 0.7 a

12.0 + 1.2 a

13.2 + 0.3 b

14.9 + 0.4 c

15.9 + 0.4 b

22.8 + 0.6 b

31.0 + 0.5 c

†Mean + standard deviation (SD).
‡Treatments with unlike letters were different (p<0.05). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Appendix Table 3. Propionate concentrations (mM †) at various time points from the in vitro incubation‡.
Treatment
0 hr
0.75 hr
1.5 hr
2.5 hr
4 hr
6 hr
12 hr
(p=0.6383)

(p=0.0207)

(p=0.083)

(p=0.0827)

(p=0.0027)

(p=0.843)

24 hr
(p=0.0076)

Control

4.7 + 0.2

5.3 + 1.3 a

5.8 + 0.3 a

7 + 0.5 a

7.1 + 0.3 a

7.8 + 0.2 a

8.2 + 0.5 a

9.3 + 0.2 ab

CFA

4.7 + 0.3

4.8 + 0.04 a

5.8 + 0.3 a

6.6 + 0.2 a

7.1 + 0.3 a

7.5 + 0.2 ab

8.0 + 0.3 a

9.5 + 0.2 a

CGA

4.7 + 0.4

5.2 + 0.3 a

6.2 + 0.1 a

6.9 + 0.1 a

7.4 + 0.2 a

7.6 + 0.4 ab

8.0 + 1.0 a

9.5 + 0.3 a

Cbx

4.7 + 0.5

5.1 + 0.3 a

6.4 + 0.5 a

6.6 + 0.2 a

7.1 + 0.1 a

7.1 + 0.2 b

8.3 + 0.2 a

8.9 + 0.3 b

†Mean + standard deviation (SD).
‡Treatments with unlike letters were different (p<0.05). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Appendix Table 4. Acetate to Propionate Ratio† at various time points from the in vitro incubation‡.
Treatment
0 hr
0.75 hr
1.5 hr
2.5 hr
4 hr
6 hr

12 hr

24 hr

(p=0.601)

(p=0.0025)

(p=0.0001)

(p<0.0001)

(p<0.0001)

(p<0.0001)

(p<0.0001)

Control

1.8 + 0.1

1.8 + 0.3 a

2.0 + 0.06 a

2.1 + 0.04 ab

2.3 + 0.01 a

2.5 + 0.04 a

3.3 + 0.04 a

4.1 + 0.07 a

CFA

1.8 + 0.2

1.8 + 0.01 a

2.0 + 0.05 ab

2.1 + 0.07 ac

2.2 + 0.04 b

2.5 + 0.01 a

3.3 + 0.02 a

4.1 + 0.01 a

CGA

1.8 + 0.3

1.9 + 0.08 a

2.0 + 0.01 a

2.2 + 0.02 b

2.3 + 0.02 a

2.6 + 0.04 b

3.4 + 0.02 b 4.2 + 0.06 b

Cbx

1.8 + 0.4

1.8 + 0.04 a

1.9 + 0.06 b

2.0 + 0.01 c

2.1 + 0.03 c

2.2 + 0.02 c

2.7 + 0.03 c

3.5 + 0.06 c

†Mean + standard deviation (SD).
‡Treatments with unlike letters were different (p<0.05). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Appendix Table 5. Butyrate concentrations (mM †) at various time points from the in vitro incubation‡.
Treatment
0 hr
0.75 hr
1.5 hr
2.5 hr
4 hr
6 hr
12 hr

24 hr

(p=0.0078)

(p=0.0692)

(p<0.0001)

(p<0.0001)

(p<0.0001)

(p<0.0001)

(p<0.0001)

Control

3.1 + 0.1

3.1 + 0.03 a

3.8 + 0.2 a

4.9 + 0.3 a

5.2 + 0.2 a

6.2 + 0.2 a

8.3 + 0.5 a

11.2 + 0.2 a

CFA

3.1 + 0.1

3.2 + 0.03 ab

3.8 + 0.2 a

4.5 + 0.2 a

5.2 + 0.2 a

6.0 + 0.2 a

8.3 + 0.4 a

11.5 + 0.2 a

CGA

3.1 + 0.1

3.4 + 0.1 b

4.1 + 0.1 a

4.7 + 0.1 a

5.4 + 0.1 a

6.1 + 0.3 a

8.3 + 1.1 a

11.3 + 0.3 a

Cbx

3.1 + 0.1

3.2 + 0.2 ab

3.8 + 0.3 a

3.9 +0.1 b

4.2 + 0.1 b

4.5 + 0.1 b

5.7 + 0.2 b

7.7 + 0.2 b

†Mean + standard deviation (SD).
‡Treatments with unlike letters were different (p<0.05). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Appendix Table 6. Valerate concentrations (mM†) at various time points from the in vitro incubation‡.
Treatment

0 hr

0.75 hr

1.5 hr

2.5 hr

4 hr

6 hr

12 hr

24 hr

(p=0.429)

(p=0.0012)

(p=0.0074)

(p=0.0107)

(p<0.0001)

(p=0.0002)

(p<0.0001)

Control

0.5 + 0.03

0.5 + 0.04 a

0.5 + 0.02 a

0.6 + 0.03 a

0.7 + 0.05 a

0.9 + 0.04 a

1.3 + 0.09 a

1.5 + 0.06 a

CFA

0.5 + 0.03

0.5 + 0.04 a

0.5 + 0.02 a

0.6 + 0.04 ab

0.7 + 0.02 ab

0.9 + 0.03 a

1.3 + 0.06 a

1.6 + 0.08 a

CGA

0.5 + 0.03

0.5 + 0.02 a

0.5 + 0.01 a

0.6 + 0.01 ab

0.8 + 0.05 b

0.9 + 0.06 a

1.3 + 0.16 a

1.5 + 0.04 a

Cbx

0.5 + 0.03

0.5 + 0.04 a

0.6 + 0.02 b

0.6 + 0.02 c

0.7 + 0.07 a

0.7 + 0.02 b

1.0 + 0.08 b

1.2 + 0.06 b

†Mean + standard deviation (SD).
‡Treatments with unlike letters were different (p<0.05). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Appendix Table 7. Isobutyrate concentrations (mM †) at various time points from the in vitro incubation‡.
Treatment

0 hr

0.75 hr

1.5 hr

2.5 hr

4 hr

6 hr

12 hr

24 hr

(p=0.0277)

(p=0.122)

(p=0.4019)

(p=0.0074)

(p=0.2178)

(p=0.3798)

(p=0.2689)

0.8 + 0.3 a

1.1 + 0.2 a

1.2 + 0.1 a

0.9 + 0.3 a

0.9 + 0.2 a

1.2 + 0.2 a

0.6 + 0.1 ab

Control

0.6 + 0.4

CFA

0.6 + 0.4

0.5 + 0.01 a

0.8 + 0.3 a

1.1 + 0.2 a

1.0 + 0.2 ab

0.7 + 0.1 a

0.8 + 0.1 a

1.5 + 0.1 a

CGA

0.6 + 0.4

0.7 + 0.1 b

1.1 + 0.01 a

1.2 + 0.1 a

1.0 + 0.2 a

0.8 + 0.3 a

0.8 + 0.2 a

1.3 + 0.2 a

Cbx

0.6 + 0.4

0.5 + 0.02 ab

1.0 + 0.3 a

1.2 + 0.03 a

0.8 + 0.2 b

0.6 + 0.02 a

1.0 + 0.2 a

1.5 + 0.4 a

†Mean + standard deviation (SD).
‡Treatments with unlike letters were different (p<0.05). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Appendix Table 8. Isovalerate concentrations (mM †) at various time points from the in vitro incubation‡.
Treatment
0 hr
0.75 hr
1.5 hr
2.5 hr
4 hr
6 hr
12 hr
(p=0.001)

(p=0.0096)

(p=0.1726)

(p=0.088)

24 hr

(p=0.0362)

(p=0.9899)

(p=0.0029)

Control

0.7 + 0.05

0.6 + 0.004 a

0.7 + 0.06 a

0.8 + 0.06 a

0.8 + 0.06 a

0.9 + 0.06 a

1.1 + 0.09 a

1.5 + 0.05 ab

CFA

0.7 + 0.05

0.6 + 0.01 a

0.7 + 0.04 a

0.8 + 0.04 a

0.8 + 0.03 a

0.8 + 0.03 ab

1.1 + 0.07 a

1.6 + 0.06 a

CGA

0.7 + 0.05

0.7 + 0.03 b

0.7 + 0.01 ab

0.8 + 0.01 a

0.9 + 0.02 a

0.9 + 0.08 ab

1.1 + 0.14 a

1.5 + 0.07 a

Cbx

0.7 + 0.05

0.6 + 0.03 ab

0.8 + 0.06 b

0.8 + 0.03 a

0.8 + 0.06 a

0.8 + 0.02 b

1.1 + 0.06 a

1.4 + 0.12 b

†

Mean + standard deviation (SD).
Treatments with unlike letters were different (p<0.05). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).

‡
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Appendix Table 9. Lactate and phenolic compound concentration (mM†) trends at various time points from the in vitro
incubation‡.
Treatment
0 hr
0.75 hr
1.5 hr
2.5 hr
4 hr
6 hr
12 hr
24 hr
(p=0.429)

(p=0.0012)

(p=0.0074)

(p=0.0107)

(p<0.0001)

(p=0.0002)

(p<0.0001)

Control

0.5 + 0.04

0.3 + 0.3 a

0.4 + 0.02 a

0.3 + 0.03 a

0.4 + 0.01 a

0.4 + 0.02 a

0.5 + 0.04 a

0.6 + 0.06 ac

CFA

0.5 + 0.04

5.5 + 0.2 b

4.9 + 0.1 b

4.6 + 0.1 b

3.6 + 0.1 b

2.7 + 0.1 b

0.7 + 0.05 b

0.7 + 0.2 ac

CGA

0.5 + 0.04

2.6 + 0.2 c

2.0 + 0.2 c

1.6 + 0.1 c

1.0 + 0.1 c

0.6 + 0.05 c

0.7 + 0.03 b

1.0 + 0.08 b

Cbx

0.5 + 0.04

0.4 + 0.3 a

0.4 + 0.03 a

0.4 + 0.03 a

0.4 + 0.03 a

0.4 + 0.01 a

0.4 + 0.02 a

0.5 + 0.1 c

†Mean + standard deviation (SD).
‡Treatments with unlike letters were different (p<0.05). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
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Appendix Table 10. Total volatile fatty acid concentrations (mM †) at various time points from the in vitro incubation‡.
Treatment
0 hr
0.75 hr
1.5 hr
2.5 hr
4 hr
6 hr
12 hr
24 hr
(p=0.0718)

(p=0.0952)

(p=0.0113)

(p=0.0006)

(p<0.0001)

(p=0.0225)

(p<0.0001)

Control

17.9 + 1.4

19.4 + 1.4 a

23.3 + 1.8 a

29.3 + 2.3 a

31.3 + 1.4 a

36.1 + 1.5 a

46.4 + 2.6 a

63.2 + 1.2 a

CFA

17.9 + 1.4

18.2 + 0.2 a

23.1 + 1.7 a

27.1 + 1.4 a

30.6 + 1.5 ab

34.5 + 0.9 a

45.8 + 2.0 ab

64.1 + 1.3 a

CGA

17.9 + 1.4

20.4 + 1.5 a

25.4 + 0.4 a

29.1 + 0.5 a

32.6 + 1.0 a

35.7 + 2.1 a

46.6 + 6.1 a

65.4 + 1.8 a

Cbx

17.9 + 1.4

18.8 + 1.2 a

24.6 + 2.3 a

26.4 + .05 b

28.5 + 0.9 b

29.6 + 0.7 b

40.0 + 1.2 b

51.8 + 1.3 b

†

Mean + standard deviation (SD).
Treatments with unlike letters were different (p<0.05). Treatments included control with no compound (Control), 500 ppm caffeic
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx).
‡
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Appendix Table 11. Bacterial correlation coefficientsa (p<0.05) for the in vitro incubation at 24 hours.
Total
C.
Total
BifidoE. coli
Lactobacilli
Coliforms
perfringens Anaerobes
bacteria
Controlb
Lactobacilli
C.
perfringens
Anaerobes
E. coli
Coliforms
% E. coli
Caffeic acidc
Lactobacilli
C. perfringens
Anaerobes
E. coli
Coliforms
% E. coli
Chlorogenic acidc
Lactobacilli
C. perfringens
Anaerobes
E. coli
Coliforms
% E. coli
Carbadoxd
Lactobacilli
C. perfringens
Anaerobes
E. coli
Coliforms
% E. coli

NSe
NS

NS

0.87605
NS
NS
NS

NS
NS
NS
0.74869

NS
NS
NS
NS

NS
NS
NS

0.89071
NS

NS

NS
NS
0.90116
NS
NS
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS

NS
NS
NS

NS
NS

NS

NS
NS
NS
NS
NS
NS

NS
NS
0.88866
NS
NS

NS
NS
NS
NS

NS
NS
NS

NS
NS

NS

0.88604
NS
0.99514
NS
NS
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS

NS
NS
NS

0.88492
NS

NS

a

r > 0.8, very high correlation; 0.8 > r > 0.6, substantial correlation.
df=7, rcrit=0.666.
c
df=4, rcrit=0.811
d
df=3, rcrit=0.878.
e
NS, Not Significant, p>0.05.

b
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Appendix Table 12. Correlation coefficientsa (p<0.05, df=10, rcriet=0.576 ) between bacterial counts and
volatile fatty acid concentrations for the in vitro incubation at 24 hoursd.
BifidoLactoC.
Total
% E.
Total
E. coli
bacteria
bacilli
perfringens
Coliform
coli
Anaerobe
Caffeic acid
Acetate
Propionate
Acetate:
Propionate
Butyrate
Valerate
Isovalerate
Isobutyrate
Total VFA
Chlorogenic
acid
Acetate
Propionate
Acetate:
Propionate
Butyrate
Valerate
Isovalerate
Isobutyrate
Total VFA

NSb
NS

NS
NS

NS
NS

NS
NS

0.77253
0.70268

NS
NS

NS
NS

NS

NS

NS

NS

NS

NS

NS

NS
NS
NS
NS
NS

0.69464
NS
0.62462
NS
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

0.70009
0.66853
0.75822
0.75685
0.75533

NS
NS
NS
NS
NS

0.68571c
NS
0.68571c
NS
0.68571c

NS
NS

NS
NS

NS
NS

-0.60152
-0.68571c

-0.69209
NS

NS
NS

0.66288
0.65714c

NS

NS

NS

NS

NS

NS

NS

-0.61283
NS
-0.66278
-0.71831
-0.69597

NS
NS
NS
NS
NS

0.61339
NS
0.59427c
0.59210
0.65740

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

c

-0.68571
NS
-0.65600
-0.70389
-0.61253

a

r > 0.8, very high correlation; 0.8 > r > 0.6, substantial correlation; 0.6 > r > 0.4, moderate correlation.
NS, not significant (p>0.05).
c
Non-linear correlation using Spearman option.
d
None of the correlations from the control or the carbadox treatment were significant (p>0.05).
b
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